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Background Angiotensin-converting enzyme and neutral endopeptidase are
endothelial metallopeptidases that metabolise bradykinin. Inhibitors of angiotensin-
converting enzyme improve symptoms and survival in patients with heart failure and
vascular disease and potentiate bradykinin-mediated vasodilatation and endothelial
tissue plasminogen activator release. The vascular actions of kinins are mediated by
an inducible Bi receptor and a constitutively expressed B2 receptor. Vascular Bi
kinin receptor expression is markedly upregulated with left ventricular dysfunction
and angiotensin-converting enzyme inhibition, but its role in man remains unclear.
Objectives The aims of this thesis were first, to confirm biological activity of kinin
receptor agonists and antagonists in human vascular tissue in vitro: second, to
determine the contribution of bradykinin to the systemic haemodynamic effects of
angiotensin-converting enzyme inhibition in patients with heart failure: third, to
determine the effects of neutral endopeptidase inhibition on the vascular actions of
bradykinin in patients treated with angiotensin-converting enzyme inhibition: fourth
and finally, to determine the contribution of the Bi kinin receptor to the vascular
actions of kinins in patients with heart failure.
Methods Myography The vasomotor effects of kinin peptides were determined using
myography of human umbilical vein rings. Heart failure: Systemic circulation After
6 weeks of enalapril or losartan therapy, patients underwent right heart
catheterisation and received an intravenous infusion of the bradykinin receptor
antagonist, B9340. Systemic haemodynamic variables were recorded. Peripheral
circulation Blood flow and plasma fibrinolytic parameters were determined in both
forearms using venous occlusion plethysmography and venous blood sampling.
Drugs were administered via the brachial artery of the non-dominant forearm. The
effect of the neutral endopeptidase inhibitor, thiorphan, on the vascular actions of
bradykinin was examined in patients maintained on angiotensin-converting enzyme
inhibition. Vascular Bi receptor function was examined using selective peptidic kinin
receptor agonists and antagonists.
Results Biological activity of kinin receptor agonists and antagonists was confirmed
in human umbilical vein. Systemic bradykinin antagonism caused an increase in
mean arterial pressure and systemic vascular resistance and attenuated the fall in
pulmonary arterial and pulmonary arterial wedge pressures in patients treated with
enalapril compared to losartan. Compared to placebo, thiorphan augmented the
vasomotor and fibrinolytic actions of bradykinin in patients treated with chronic
angiotensin-converting enzyme inhibition. Bi receptor agonism and antagonism had
no effect on vascular tone or enothelial tissue plasminogen activator release in the
presence or absence of angiotensin-converting enzyme inhibition. The B2 receptor
agonist, bradykinin, caused vasodilatation and tissue plasminogen activator release
and these effects were markedly augmented by angiotensin-converting enzyme
inhibition.
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Conclusions Bradykinin contributes to the systemic haemodynamic effects of long-
term angiotensin-converting enzyme inhibition in patients with heart failure. Neutral
endopeptidase contributes to the metabolism of bradykinin in patients with heart
failure maintained on angiotensin-converting enzyme inhibitor therapy. Our findings
may explain some of the apparent clinical differences between angiotensin-
converting enzyme inhibitors and angiotensin receptor blockers, as well as the
greater vasodepressor effect observed with combined angiotensin-converting enzyme
and neutral endopeptidase inhibition when compared to angiotensin-converting
enzyme inhibition alone. Finally, the Bj kinin receptor does not appear to have a
major vasomotor or fibrinolytic role in patients with heart failure. Augmentation of
kinin-mediated vasodilatation and tissue plasminogen activator release by
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1.1 THE KALLIKREIN-KININ SYSTEM
A role for the kallikrein-kinin system in vascular homeostasis was first recognised in
1909 following the demonstration that intravenous injection of fractions extracted
from human urine resulted in a transient reduction in blood pressure [Abelous and
Bardier, 1909]. Since then, a substantial body of evidence has implicated kinins in a
wide range of physiological and pathological processes, including inflammation
[Couture et al, 2001], nocioception [Millan, 1999], smooth muscle contraction
[Khairallah and Page, 1963], vascular homeostasis [Benjamin et al, 1989; Labinjoh
et al, 2000], blood coagulation [Kaplan and Silverberg, 1987] and fibrinolysis
[Brown et al, 2000; Labinjoh et al, 2000],
The kallikrein-kinin system can be broadly divided into a plasma-based pathway that
results in the formation of the nonapeptide, bradykinin, and a tissue-based pathway
producing the decapeptide, Lys-bradykinin (kallidin; Figure 1). Removal of the N-
terminal lysine residue from Lys-bradykinin by a plasma aminopeptidase will also
result in the generation of bradykinin. Under pathophysiological conditions, such as
tissue injury or inflammation, plasma and tissue kallikreins are activated and release
bradykinin and Lys-bradykinin through cleavage of high and low molecular weight
kininogens respectively.
1.1.1 The Plasma Kallikrein-Kinin System
Bradykinin is released into plasma from high molecular weight kininogen following
cleavage by the serine protease, plasma kallikrein [Regoli and Barabe, 1980;
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Bhoola et al, 1992], Plasma kallikrein and high molecular weight kininogen are both
synthesised in the liver. Kallikrein is synthesised and secreted as the precursor,
prekallikrein, whereas high molecular weight kininogen is stored in hepatocytes and
undergoes glycolyslation prior to secretion [Bhoola et al, 1992], Plasma prekallikrein
circulates in plasma as a heterodimer bound to high molecular weight kininogen
[Mandle et al, 1976] and is activated by coagulation factor Xlla (Hageman factor)
and endothelium-derived prekallikrein activators, such as serine protease
prolylcarboxypeptidase [Mandle and Kaplan, 1977; Shariat-Madar et al, 2002],
Initially, the liberation of bradykinin was assumed to occur only as a result of
"contact activation" of factor XII by negatively charged surfaces. Recently, however,
it has been recognised that the components of the plasma kallikrein system may also
be assembled and activated on the intravascular surface of endothelial cells through
binding to a cell surface receptor complex containing cytokeratin 1, urokinase
plasminogen activator (u-PA) receptor and gClqR (Figure 2) [Joseph et al, 1996;
Colman et al, 1997],
1.1.2 The Tissue Kallikrein-Kinin System
The tissue kallikreins are a multigene family of enzymes present in a number of
organs including the heart, kidney, pancreas and salivary glands [Bhoola et al, 1992;
Marceau et al, 1998]. Three tissue kallikrein enzymes have been identified in man
[Marceau et al, 1998], These enzymes are synthesised in cells as a precursor and
converted to their active form by cleavage of an amino-terminal peptide [Takada et
al, 1985]. Once activated, the tissue kallikreins preferentially release Lys-bradykinin
from low molecular weight kininogen. Tike high molecular weight kininogen, low
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Figure 2. Assembly and activation of the plasma kallikrein-kinin system (KKS) on endothelial cells.
Plasma prekallikrein (PK) circulates in complex with high molecular weight kininogen (HK). The
HK«PK complex binds to a multiprotein receptor complex that consists of cytokeratin 1 (CK1),
urokinase plasminogen activator receptor (uPAR) and gClqR. The proteins of the HK*PK receptor
complex co-localise on endothelial cell membranes. When HK-PK binds to endothelial cells, PK is
rapidly converted to kallikrein (K) by the enzyme prolylcarboxypeptidase (PRCP), which is
constitutively active on endothelial cell membranes. The resulting kallikrein autodigests its receptor,
HK, to liberate bradykinin (BK), which can liberate tissue plasminogen activator (tPA), nitric oxide
(NO), and prostacyclin (PGI2) lfom endothelial cells. Kallikrein also activates FXII, which binds to
the same multiprotein receptor complex as HK in its absence. In this hypothesis for assembly and
activation of the proteins of the plasma KKS, FXII is activated by kallikrein after PK activation.
ScuPA, single chain urokinase plasminogen activator.[Schmaier, 2002]
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molecular weight kininogen is also synthesised in the liver and is present in plasma
and other body fluids.
1.2 KININ METABOLISM
The rapid metabolism of bradykinin by a number of peptidases (Figure 3) ensures a
half-life in blood of <15 seconds [McCarthy et al, 1965; Ferreira and Vane, 1967;
Bonner et al, 1990], Kininase II (angiotensin-converting enzyme (ACE) or dipeptidyl
carboxypeptidase, EC 3.4.15.1) and neutral endopeptidase (enkephalinase,
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neprilysin, EC.3.4.24.11; NEP) both hydrolyse the Pro -Phe bond at the carboxy-
terminus of the kinin molecule (Figure 3). Kininase II also splits the Phe5-Ser6 bond.
The plasma carboxypeptidases, collectively known as kininase I, include
carboxypeptidase N (EC 3.4.17.3) and carboxypeptidase B (thrombin activatable
fibrinolysis inhibitor (TAFI), carboxypeptidase R or U). Enzymes with kininase I
activity cleave the carboxyl-terminal from bradykinin resulting in the formation of
des-Arg9-bradykinin. The half-life of des-Arg9-bradykinin appears to be 4- to 12-fold
greater than bradykinin [Decarie et al, 1996; Blais et al, 1997] and may explain why
plasma concentrations of des-Arg9-bradykinin are greater than bradykinin in vivo.
1.3 KININ RECEPTORS
The biological effects of kinins in man are mediated by two principal G-protein
coupled receptors, Bi and B2, each with high affinity and specificity for their
respective ligands, des-Arg9-bradykinin and bradykinin [Leeb-Lundberg et al, 2005].
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Figure 3. Amino acid structure and C-terminal sites of enzymatic degradation of bradykinin and
des-Arg9-bradykinin.
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The Bi and B2 kinin receptors share only 36% homology with each other and are
distinguishable on the basis of their pharmacological and molecular characteristics
[Hess et al, 1992; Menke et al, 1994; Marceau et al, 1998; Leeb-Lundberg et al,
2005]. Both receptors consist of seven helical transmembrane domains (Figure 4),
the specificity of receptor binding being determined largely by the sixth
transmembrane domain [Leeb et al, 1997],
1.3.1 Peptide Agonists
Binding affinity estimates for the two human kinin receptor subtypes are shown in
Table 1. Removal of the C-terminal arginine favours affinity for the Bi receptor and
reduces affinity at the B2 receptor. The only naturally occurring kinin peptide with
subnanomolar affinity at the human Bj receptor is Lys-des-Arg9-bradykinin.
1.3.2 Peptide Antagonists
The development of selective peptidic kinin receptor antagonists has greatly
facilitated investigation of kinin receptor subtypes (Table 2). In keeping with the
kinin receptor agonists, the N-terminal lysine residue confers a greater affinity for the
Bi receptor in man. Lys-[Leu8]-des-Arg9-bradykinin, therefore, is the optimal Bi
receptor antagonist based on naturally occurring amino acids. B9340 is a synthetic
peptidic antagonist that has similar affinity for both the Bi and B2 kinin receptors.
The rapid elimination and short duration of action, coupled with the competitive,
reversible nature of receptor blockade make these peptides ideal pharmacological








Figure 4. Transmembrane structure of the human B, and B2 kinin receptors. [Leeb-Lundberg et
at, 2005]
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1.3.3 Intracellular Signalling Mechanisms
The Bj and B2 kinin receptor subtypes belong to the G-protein coupled receptor
superfamily. Although the identity and importance of specific G-protein subunits
associated with each receptor subtype are similar, the intracellular transduction
mechanisms associated with kinin receptor signalling varies between cell types.
Second messenger systems include phospholipase C and phosholipase A2 that once
activated cause a rise in intracellular calcium, inositol phosphate and diacylglycerol.
Additional downstream signalling effects include an increase in cyclic AMP and
cyclic GMP, activation of protein kinase C and mitogen activated protein kinases,
and release of prostaglandins, nitric oxide and endothelium-derived hyperpolarising
factor [Levesque et al, 1995; Marceau et al, 1998; Christopher et al, 2001].
Interestingly, Bi receptor activation appears to be associated with a more persistent
intracellular signal than the B2 receptor suggesting, perhaps, that Bi receptor
activation may lead to more chronic and persistent changes [Mathis et al, 1996;
Austin etal, 1997].
1.3.4 Receptor Desensitisation
Kinin receptors differ significantly in their susceptibility to undergo desensitisation.
Following agonist mediated activation, the B2 receptor agonist complex is rapidly
internalised and sequestered in calveolae along with associated G-proteins, greatly
reducing the availability of unbound B2 receptors on the cell surface [Sabourin et al,
2002a], In contrast, the Bi receptor does not undergo internalisation or significant
desensitisation. These differences have been attributed to amino acid sequences in
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the cytoplasmic carboxyl terminal of the B2 receptor, absent from the cytoplasmic
domain of the Bi receptor [Faussner et al, 1998].
1.4 KININ RECEPTOR EXPRESSION AND FUNCTION
1.4.1 B2 Kinin Receptor
The B2 receptor is the most prevalent receptor subtype expressed under physiological
conditions. It is found on the surface of many cell types, including the vascular
endothelium and smooth muscle, where it mediates the actions of bradykinin. In
animal models, intravascular administration of bradykinin causes arterial
vasodilatation and a fall in blood pressure [Regoli and Barabe, 1980], In man,
activation of the endothelial B2 receptor stimulates endothelium-dependent
vasodilatation and release of the pro-lytic factor, tissue plasminogen activator (t-PA),
and these effects can be blocked by B2 receptor antagonists [Benjamin et al, 1989;
Groves et al, 1995; Brown et al, 2000; Labinjoh et al, 2000],
1.4.2 Bi Kinin Receptor
In contrast to the B2 receptor, the vascular Bi receptor is normally expressed very
weakly but is rapidly upregulated in the presence of inflammation [Sardi et al, 1998;
McLean et al, 1999; Sardi et al, 1999; McLean et al, 2000b], ischaemic left
ventricular dysfunction [Tschope et al, 2000], cardiovascular disease [Raidoo et al,
1997; McLean et al, 2000b] and ACE inhibition [Nwator and Whalley, 1989; Marin-
Castano et al, 2002], In animal models, stimulation of the Bi receptor produces
vasodilatation and a reduction in blood pressure [Drapeau et al, 1991; Nakhostine et
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al, 1993; Deblois and Horlick, 2001], Intense endothelial Bi receptor expression has
been demonstrated in atheromatous human blood vessels [Raidoo et al, 1997] and Bi
receptor stimulation induces dose-dependent vasodilatation in human coronary
arteries in vitro [Drummond and Cocks, 1995b],
1.4.3 Upregulation of Bi Kinin Receptor Expression
Functional expression of the Bi kinin receptor has traditionally been characterised by
smooth muscle responses to selective kinin receptor agonists in organ bath
preparations. Tissues from a variety of vascular sites and species, including human
umbilical vein and coronary artery, examined in this way exhibit Bj receptor
mediated responses which are absent initially but develop in magnitude as a function
of the in vitro incubation time [Bouthillier et al, 1987; Drummond and Cocks, 1995b;
Gobeil et al, 1996; Sardi et al, 1998; Sardi et al, 1999]. These responses can also be
invoked by pre-incubation of tissue with bacterial lipopolysaccharide or
inflammatory cytokines, such as interleukin-1 (3 [Sardi et al, 1998] and tumour
necrosis factor-a [Sardi et al, 1999].
These in vitro findings have been confirmed ex vivo and in vivo in a number of
animal models [Marceau, 1995; McLean et al, 1999]. As an example, endotoxaemia
induces endothelial expression of Bi receptors and des-Arg9-bradykinin causes
endothelium-dependent vasodilatation of the coronary arteries [McLean et al, 1999].
In addition, it has been reported that des-Arg9-bradykinin can cause coronary
resistance and conduit vessel dilatation even in the absence of inflammation [Su et al,
2000], In man, upregulation of Bi receptor expression in the presence of
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inflammation has been demonstrated in vivo in the nasal mucosa of patients with
allergic airways disease [Christiansen et al, 2002].
1.4.4 Intracellular Mechanisms of Bi ReceptorUpregulation
The induction of Bi receptor responses is attenuated in tissues treated with the
protein synthesis inhibitors, cycloheximide and anisomycin, and the protein
trafficking inhibitor, Brefeldin A [Deblois et al, 1991; Audet et al, 1994; Sabourin et
al, 2002b]. Brefeldin A selectively inhibits translocation of proteins from the
endoplasmic reticulum to the Golgi apparatus, the expected maturation pathway for a
G-protein coupled receptor. In addition, the nuclear transcription factor, NF-kP, has
been implicated in the induction of Bi receptor expression [Ni et al, 1998; Schanstra
et al, 1998], NF-kP binding domains have been identified in the promoter region of
the human Bi receptor gene [Ni et al, 1998; Schanstra et al, 1998] and cytokine-
induced Bi kinin receptor expression is blocked by pharmacological inhibitors of
NF-Kp [Sabourin et al, 2002b; Passos et al, 2004], Similarly, the protein
glycosylation inhibitor, tunicamycin, partially and selectively inhibits B] responses
suggesting post-translational modification prior to cell surface expression of Bi
receptors [Audet et al, 1994], Cytokine mediated stabilisation of Bi receptor mRNA
has also been implicated in the upregulation of Bi receptor expression on the cell
surface [Fladdad et al, 2000], Thus, increased Bi receptor expression appears to result
from de novo receptor synthesis and occurs over a time period of 2-3 hours.
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1.4.5 Bi Kinin Receptor Expression, Atherosclerosis and Cardiac
Failure
Systemic inflammation plays an important role in the pathogenesis of atherosclerosis
[Ross, 1999] and cardiovascular disease [Levine et al, 1990; Ridker et al, 2000]. In
keeping with this, an inducible Bi receptor response has been reported in vivo in
animal models of myocardial ischaemia [Mazenot et al, 2001] and infarction
[Tschope et al, 2000; Tschope et al, 2004], and balloon angioplasty induced vascular
injury [Agata et al, 2000], In man, autopsy studies have indicated that Bi receptors
are markedly upregulated in the presence of atherosclerosis [Raidoo et al, 1997],
Patients with chronic heart failure have significant elevations in plasma cytokine
concentrations including tumour necrosis factor-a [Levine et al, 1990; McMurray et
al, 1991; Kelly and Smith, 1997]. Such patients not only demonstrate marked
endothelium-dependent vasomotor dysfunction [Kubo et al, 1991; Katz et al, 1992],
but this dysfunction is highly correlated with plasma tumour necrosis factor-a
concentrations [Katz et al, 1994], In the face of such systemic inflammation,
therefore, it is likely that the expression of kinin receptors will favour the Bj
receptor. However, the effects of vascular Bi receptor agonism and antagonism and




Angiotensin-converting enzyme (kininase II) is a membrane-bound metallopeptidase
present on the vascular endothelium. First described for its ability to convert
angiotensin I to angiotensin II, ACE also metabolises bradykinin [Erdos and Yang,
1967], Indeed, ACE has greater affinity for bradykinin than for angiotensin I
[Jaspard et al, 1993] and is the principal enzyme responsible for the rapid turnover of
bradykinin and its metabolites [Decarie et al, 1996; Blais et al, 1997; Cyr et al,
2001]. Therefore, inhibitors of ACE will not only block the formation of angiotensin
II, but will also inhibit the breakdown of bradykinin. As a result, plasma angiotensin
I concentrations and renin activity increase, whereas circulating concentrations of
angiotensin II and aldosterone fall [Gavras et al, 1978]. Although the short half-life
of bradykinin makes accurate measurement of plasma concentrations difficult,
elevated plasma bradykinin concentrations have been reported in the presence of
ACE inhibition [Pellacani et al, 1994].
1.5.2 Physiological Effects of Angiotensin-Converting Enzyme
Inhibition
Inhibitors of ACE reduce blood pressure and systemic vascular resistance in a dose-
dependent manner with little change in heart rate [Powers et al, 1982; Beermann et
al, 1993; Flammang et al, 1993; Mitrovic et al, 1996]. In patients with left ventricular
systolic impairment, ACE inhibitors reduce pulmonary artery wedge pressure and
increase cardiac output and these changes persist following 3 months of ACE
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inhibitor therapy [Beermann et al, 1993; Flammang et al, 1993; Mitrovic et al, 1996].
In the kidney, ACE inhibitors increase renal blood flow without affecting glomerular
filtration rate and promote a natriuresis [Hollenberg, 1988],
1.5.3 Angiotensin-Converting Enzyme Inhibition and Endothelial
Function
Angiotensin-converting enzyme inhibitors reverse endothelial dysfunction in a
number of conditions associated with the development of congestive heart failure
including hypertension, coronary artery disease and non-insulin-dependent diabetes
mellitus [Antony et al, 1996; O'Driscoll et al, 1999; Anderson et al, 2000; Hornig et
al, 2001], In patients with heart failure, treatment with the ACE inhibitor, quinapril,
increases nitric oxide availability and augments endothelial-dependent vasodilatation
[Hornig et al, 1998]. Similarly, ACE inhibitors may improve endogenous fibrinolytic
parameters in patients with heart failure [Goodfield et al, 1999] through inhibition of
angiotensin Il-mediated synthesis of plasminogen activator inhibitor type-1 (PAI-1)
[Ridker et al, 1993] and potentiation of bradykinin-stimulated endothelial t-PA
release [Witherow et al, 2002],
1.5.4 Clinical Effects of Angiotensin-Converting Enzyme Inhibitor
Therapy
A number of landmark trials over the last two decades have demonstrated that ACE
inhibitors reduce morbidity and mortality in patients with heart failure due to left
ventricular systolic impairment [CONSENSUS, 1987; SOLVD, 1991]. These
impressive benefits appear to be dose-dependent [Packer et al, 1999] and extend to
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patients with asymptomatic left ventricular dysfunction [SOLVD, 1992], In a recent
meta-analysis, data pooled from five major trials evaluating ACE inhibitors in
patients with heart failure and myocardial infarction demonstrated a significant
reduction in rates of mortality, reinfarction and hospitalisation with ACE inhibitor
therapy when compared to placebo [Flather et al, 2000].
Although the reduction in mortality may be primarily due to the prevention of
progression of heart failure, there is increasing evidence that ACE inhibitors have
anti-ischaemic properties [Pfeffer et al, 1992; Yusuf et al, 1992], In patients with left
ventricular dysfunction - with or without symptoms of heart failure - treatment with
an ACE inhibitor reduced the risk of myocardial infarction or sudden cardiac death
by 20% [Pfeffer et al, 1992; Yusuf et al, 1992], More recently, these benefits have
been shown to extend to high-risk patients with normal left ventricular function. The
HOPE study demonstrated that in patients with normal left ventricular function and
known vascular disease or diabetes mellitus plus one other cardiovascular risk factor,
ACE inhibition significantly reduced mortality and recurrent ischaemic events by
22% [Yusuf et al, 2000]. These findings are supported by the recent EUROPA trial
which demonstrated a significant reduction in the combined endpoint of
cardiovascular death, myocardial infarction or cardiac arrest with perindopril when
compared to placebo in patients with stable coronary artery disease in the absence of
symptomatic heart failure [Fox, 2003]. Although a number of mechanisms including
blood pressure reduction, reversal of endothelial dysfunction and alterations in
endogenous fibrinolysis have been implicated, the exact mechanisms by which ACE
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inhibitors prevent ischaemic vascular events remain unclear [Brown and Vaughan,
1998],
1.5.5 Angiotensin-Converting Enzyme Inhibition and Bradykinin
There is now substantial evidence that the haemodynamic and clinical effects of
ACE inhibitor therapy may be due, at least in part, to the inhibition of bradykinin
metabolism [Gainer et al, 1998; Witherow et al, 2001], At a functional level, ACE
inhibition potentiates the vascular actions of bradykinin in the human forearm
[Benjamin et al, 1989; Labinjoh et al, 2001; Witherow et al, 2002] and coronary
[Kuga et al, 1997] circulations and in healthy volunteers and patients with
hypertension, bradykinin antagonism attenuates the vasodepressor response to acute
ACE inhibition [Gainer et al, 1998; Squire et al, 2000], We have recently
demonstrated that intra-arterial administration of the combined Bi and B2 kinin
receptor antagonist, B9340, causes vasoconstriction in the forearm circulation of
patients with heart failure maintained on chronic ACE inhibitor therapy [Witherow et
al, 2001]. In contrast, intra-arterial E1OE-140, a selective B2 receptor antagonist has
no effect on forearm blood flow in patients treated with ACE inhibition [Davie et al,
1999; Witherow et al, 2001]. This disparity may reflect the differing pharmacological
profiles of the bradykinin antagonists used and provides the first, albeit indirect,
evidence of a vasomotor role for the Bi kinin receptor in vivo in man.
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1.5.6 Angiotensin-Converting Enzyme Inhibition and Bi Receptor
Responses
Inhibitors of ACE not only increase bradykinin concentrations but also augment
production of des-Arg9-bradykinin. Under physiological conditions, the percentage
of bradykinin metabolised to des-Arg9-bradykinin by plasma carboxypeptidases is
limited (~1% - 11%) [Decarie et al, 1996; Blais et al, 1997; Cyr et al, 2001]. In the
presence of ACE inhibition, however, this figure increases significantly to -50%
[Cyr et al, 2001]. Thus ACE inhibition will potentially favour the augmentation of
both Bi and B2 kinin receptor mediated effects [Lamontagne et al, 1995].
There is evidence that ACE inhibition can lead to upregulation of Bi receptor
expression in vivo [Nwator and Whalley, 1989; Marin-Castano et al, 2002], although
this finding remains controversial [Marceau et al, 1999], Recently, Marin-Castano
and colleagues demonstrated increased expression of functional Bi receptors in both
renal and vascular tissues in rats exposed to chronic ACE inhibitor therapy. This
induction was independent of the B2 kinin receptor and contributed to the
hypotensive effect of ACE inhibitor therapy [Marin-Castano et al, 2002], Previous
work in vitro has suggested that Bi agonism can induce upregulation of its own
receptor [Schanstra et al, 1998; Phagoo et al, 1999]. Given the anticipated
augmentation of des-Arg9-bradykinin concentrations associated with ACE inhibition,
this mechanism may have contributed to the observed increase in B] receptor
expression [Marin-Castano et al, 2002], Whether ACE inhibition induces functional
Bi receptor expression in human vascular tissue in vivo is not known.
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1.6 NEUTRAL ENDOPEPTIDASE
Neutral endopeptidase is a glycosylated metallopeptidase that colocalises with ACE
on the cell membrane and is found in a wide variety of tissues including the vascular
endothelium [Roques et al, 1993]. Neutral endopeptidase has a broad substrate
specificity, metabolising a number of biologically active peptides including
endothelin-1, atrial natriuretic peptide, substance P and bradykinin [Roques et al,
1993], This lack of substrate selectivity may account for the heterogeneity observed
with the vasomotor and haemodynamic effects of isolated NEP inhibition in man
[Northridge et al, 1989; Richards et al, 1990 Bevan et al, 1992; Favrat et al, 1995;
Northridge et al, 1999].
Expression of NEP is upregulated in patients with heart failure [Fielitz et al, 2002;
Knecht et al, 2002] and, in the presence of ACE inhibition, the contribution ofNEP
to bradykinin metabolism is increased [Dumoulin et al, 2001], Inhibition of NEP
potentiates the half-life of bradykinin [Graf et al, 1993] and augments bradykinin-
mediated vasodilatation in vitro [Krassoi et al, 2003], It is not known whether NEP
inhibition augments the half-life of Lys-des-Arg9-bradykinin. Indeed, it has been
suggested that the Phe8 residue may protect Bi ligands from degradation by NEP
[Marceau et al, 1998]. Although the effects of NEP inhibition on systemic
haemodynamics are variable [Northridge et al, 1989; Richards et al, 1990 Bevan et
al, 1992; Favrat et al, 1995; Northridge et al, 1999], clinical improvements have been
reported during NEP inhibition in patients with heart failure [Northridge et al, 1999].
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Co-administration of ACE and NEP inhibitors may confer additional therapeutic
efficacy. Combined ACE and NEP inhibition attenuates bradykinin degradation more
effectively than either enzyme alone [Dumoulin et al, 2001] and in animal models,
improves cardiac remodelling and survival to a greater extent than isolated ACE
inhibition [Trippodo et al, 1999], These cardioprotective effects are lost in transgenic
mice lacking the B2 kinin receptor [Xu et al, 2004]. In man, combined ACE and NEP
inhibition reduces blood pressure to a greater extent than inhibition of either enzyme
alone [Favrat et al, 1995; Campese et al, 2001] and is associated with symptomatic
and haemodynamic improvements in patients with heart failure [McClean et al,
2000]. The hypothesis that combined ACE and NEP inhibition may improve
symptoms and survival in patients with heart failure to a greater extent than ACE
inhibition alone has recently been evaluated in a large-scale clinical trial
(OVERTURE) [Packer et al, 2002], Although OVERTURE failed to demonstrate a
significant reduction in all-cause mortality with the combined ACE and NEP
inhibitor, omapatrilat, when compared to enalapril, omapatrilat did reduce the
combined secondary endpoint of cardiovascular death and hospitalisation [Packer et
al, 2002], It remains to be established whether combined ACE and NEP inhibition
augments the vascular actions of bradykinin to a greater extent than ACE inhibition
alone in patients with heart failure.
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1.7 KININS, ENDOGENOUS FIBRINOLYSIS AND ATHEROTHROMBOSIS
1.7.1 The Endogenous Fibrinolytic System
The endogenous fibrinolytic pathway describes a complex process involving the
hydrolytic cleavage of fibrin, by plasmin, to cause clot dissolution and generate
fibrin degradation products (Figure 5). Plasmin, a serine protease, is generated by the
action of an array of enzymes and inhibitors which have a coordinated action on the
zymogen, plasminogen. The major role of this enzymatic system is to protect the
circulation from intravascular fibrin formation and thrombosis that would otherwise
result in vessel occlusion and tissue ischaemia.
There are two endogenous plasminogen activators responsible for the initiation of
fibrinolysis: t-PA and u-PA. The main physiological plasminogen activator involved
in the degradation of intravascular fibrin is t-PA (Figure 6) [Astedt, 1979; Kok,
1979], Tissue plasminogen activator is released from the endothelium through the
translocation of a dynamic intracellular storage pool and the efficacy of plasminogen
activation and fibrin degradation is determined by the relative balance between the
acute local release of t-PA and its subsequent inhibition through formation of
complexes with the serpin, PAI-1.
1.7.2 Endogenous Fibrinolysis and Atherothrombosis
There is substantial evidence that the endogenous fibrinolytic system plays a crucial
role both in the acute thrombotic consequences of plaque disruption and the chronic
processes of atherogenesis. Reperfusion of the infarct-related artery occurs
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Figure 5. The Coagulation and Fibrinolytic Systems
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Figure 6. Protein structure of tissue plasminogen activator
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spontaneously in a third of patients with acute myocardial infarction within 12 hours
of the onset of symptoms [DeWood et al, 1980; Armstrong et al, 1989] and in both
healthy individuals [Meade et al, 1993] and patients with cardiovascular disease
[Jansson et al, 1993], reduced plasma fibrinolytic activity is associated with an
increased risk ofmyocardial infarction. Detailed postmortem studies have shown that
plaque growth is induced by episodic subclinical plaque disruption and thrombus
formation [Mann and Davies, 1999]. The prolonged presence of residual thrombus
over a disrupted or eroded plaque will provoke smooth muscle migration and the
production of new connective tissue, leading to plaque expansion [Mann and Davies,
1999]. Consistent with this, enhanced macrovascular fibrin deposition and
atherogenesis are seen in genetic murine models of t-PA deficiency [Christie et al,
1999],
If endogenous fibrinolysis is to be effective then rapid mobilisation of t-PA from the
endothelium is essential, because thrombus dissolution is much more effective if
t-PA is incorporated during rather than after, thrombus formation [Fox et al, 1985].
The capacity of endothelial cells to release t-PA from intracellular storage pools, and
the rapidity with which this can be mobilised, may not necessarily be reflected in the
basal plasma concentrations of t-PA antigen or activity. Using a novel model to
assess the acute endogenous fibrinolytic potential within the forearm and coronary
circulations in vivo in man [Newby et al, 1997b], we have demonstrated that acute
t-PA release is impaired in smokers [Newby et al, 1999] and in patients with
atherosclerosis and the degree of fibrinolytic impairment correlates inversely with
atherosclerotic plaque load [Newby et al, 2001],
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1.7.3 Kinins, Endogenous Fibrinolysis and Atherothrombosis
Bradykinin is released during the contact phase of coagulation when high molecular
weight kininogen is cleaved by kallikrein to produce a disulphide-linked light and
heavy chain [Schiffman et al, 1980; Reddigari and Kaplan, 1988], Although an
inflammatory mediator, bradykinin is also a potent endothelial cell stimulant that can
induce the acute release of t-PA from the endothelium [Brown et al, 1999; Labinjoh
et al, 2000] through a B2 receptor mechanism [Brown et al, 2000], Thus, following
activation of the intrinsic coagulation pathway, the liberation of bradykinin may
represent an important negative feedback loop in which bradykinin-induced t-PA
release inhibits thrombus formation within the vascular lumen when localised
endothelial denudation occurs. Moreover, this process is further amplified by the
action of plasmin itself which, in combination with kallikrein, augments bradykinin
release from high molecular weight kininogen [Kleniewski et al, 1992].
Inhibition of ACE enhances bradykinin-induced t-PA release in healthy volunteers
~2-fold [Labinjoh et al, 2001], Moreover, in an unblinded, non-randomised study in
patients with heart failure, ACE inhibition markedly augmented bradykinin-induced
t-PA release (~6- to 10-fold) such that local concentrations of t-PA approach those
seen during systemic thrombolytic therapy for acute myocardial infarction
[Witherow et al, 2002], Given the enhanced activation of the kallikrein system and
increased bradykinin release seen in clinical studies of patients with unstable angina
[Hoffmeister et al, 1995], ACE inhibition may have major beneficial effects on the
acute local fibrinolytic balance by markedly enhancing bradykinin-induced t-PA
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release in areas of intravascular thrombus formation. Consistent with this, intra¬
arterial enalprilat administration increases basal t-PA release in the forearm
circulation of healthy volunteers and this effect was blocked by the co-administration
of the B2 receptor antagonist, HOE-140 [Pretorius et al, 2003]. Whether combined
ACE and NEP inhibition augments bradykinin-induced t-PA release to a greater
extent than ACE inhibition alone has not been investigated. Moreover, it has yet to
be established whether Bi kinin receptor agonism causes t-PA release in man.
1.8 HYPOTHESES
In human umbilical vein in vitro:
1. The Bi receptor agonist, Lys-des-Arg9-bradykinin, causes dose-dependent
vasoconstriction that is selectively inhibited by the B] antagonist, Lys-des-
on ,
[Leu ]-Arg -bradykinin, and by the combined kinin receptor antagonist,
B9340.
2. The B2 receptor agonist, bradykinin, causes dose-dependent vasoconstriction
that is selectively inhibited by the B2 antagonist, HOE-140, and by the
combined kinin receptor antagonist, B9340.
In patients with heart failure in vivo:
1. Bradykinin contributes to the systemic haemodynamic effects of long-term
ACE inhibition in patients with heart failure.
2. Combined ACE and NEP inhibition augments the vascular action of
bradykinin to a greater extent than ACE inhibition alone.
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3. The B] kinin receptor mediates vasodilatation and endothelial t-PA release in
the peripheral circulation of patients with heart failure treated with ACE
inhibition.
1.9 AIMS
The aims of the thesis were:
In human umbilical vein rings (Chapter 3):
• To establish the biological activity of custom-made, selective peptidic kinin
receptor agonists and antagonists.
In patients with heart failure treated with long-term ACE inhibition
(Chapter 4):
• To determine whether the combined kinin receptor antagonist, B9340, alters
systemic haemodynamics.
In patients with heart failure treated with long-term ACE inhibition (Chapter
5):
• To determine whether local NEP inhibition augments bradykinin-mediated
vasodilatation and endothelial t-PA release in the forearm vascular bed.
• To determine whether the Bi kinin receptor agonist, Lys-des-Arg9-
bradykinin, mediates vasodilatation or endothelial t-PA release in the forearm
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vascular bed, and if so, to establish whether these effects are augmented by
local NEP inhibition.
• To determine whether atrial natriuretic peptide stimulates endothelial t-PA
release in the forearm vascular bed.
• To determine whether local NEP inhibition augments atrial natriuretic
peptide-mediated vasodilatation in the forearm vascular bed.
In patients with heart failure (Chapter 6):
• To determine the effects of selective Bi kinin receptor agonism and
antagonism on vasodilatation and endothelial t-PA release in the forearm
vascular bed.
• To establish the effects of ACE inhibition on Bi kinin receptor mediated
responses in the forearm vascular bed.
• To confirm the effects of ACE inhibition on B2 kinin receptor mediated




UMBILICAL VEIN MYOGRAPHY, IMMUNOHISTOCHEMISTRY AND
MEASUREMENT OF FOREARM BLOOD FLOW, SYSTEMIC




A wide variety of techniques exist for assessing vascular function both in vitro and in
vivo. A general overview of the techniques employed in this thesis is detailed below.
Details specific to each study can be found in the methods sections of subsequent
chapters.
Myography of isolated vascular tissue in vitro is an accurate and reproducible
method by which to determine vessel specific vasomotor responses to peptide
agonists and antagonists. The major advantage of this in vitro technique is that it
allows precise and controlled alterations in the local physiological conditions to be
made. Extrapolating the results ofmyography studies to a vascular bed in vivo can be
difficult, however, as vascular responses may vary significantly depending on the
size and type of vessel studied.
These limitations can be largely overcome by combining regional intra-arterial
forearm infusion with bilateral venous occlusion plethysmography. This technique
allows a direct assessment of peripheral vascular responses to be made in vivo using
doses 10- to 1,000-fold lower than those required to produce a systemic effect
[Benjamin et al, 1995; Webb, 1995], This dose reduction ensures a reduction in the
risk of unwanted or potentially harmful side effects whilst minimising the risk of the
confounding cardiac, renal and nervous system reflexes which can occur with
systemic dosing. Using these techniques to increase our understanding of tissue and
vascular bed specific responses to drug administration will improve our ability to
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predict systemic vascular responses and target and design invasive systemic studies
appropriately.
Systemic haemodynamic responses to drug administration in vivo in man are
determined not only by the concomitant effects in different vascular beds, such as the
cerebral, pulmonary and coronary circulations, but also by changes in heart rate,
myocardial contractility and neurohumoral reflexes [Webb, 1995], Although a
number of invasive and non-invasive techniques exist for assessing systemic
haemodynamic changes following drug administration, pulmonary artery
catheterisation remains the gold standard [Swan et al, 1970],
2.1.1 Human Umbilical Vein Myography
Myography of isolated vessels from animals has been used traditionally as a sensitive
and reliable method with which to examine the vascular effects of the Bj and B2
kinin receptors in vitro (Figure 7). Recently, however, Bi kinin receptor vasomotor
responses have been identified in two human tissues, human umbilical vein [Gobeil
et al, 1996; Sardi et al, 1998; Sardi et al, 1999] and coronary artery [Drummond and
Cocks, 1995b], Of these, the pharmacological responses of human umbilical vein
have been characterised most extensively. For this reason, combined with the
obvious practical and ethical constraints associated with obtaining viable human
coronary artery, we chose to confirm the biological activity of our custom-made
kinin peptides in vitro using myography of human umbilical vein.
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2.1.2 Forearm Resistance Vessels
Venous occlusion plethysmography, combined with unilateral brachial artery
infusion of pharmacological agonists and antagonists, is a powerful and reproducible
method for directly assessing vascular receptor physiology in the forearm circulation
in vivo (Figure 8) [Wilkinson et al, 2001], This technique has been utilised very
successfully to demonstrate that bradykinin stimulates vasodilatation [Cockcroft et
al, 1994] and endothelial t-PA release [Brown et al, 2000] via the B2 kinin receptor in
the peripheral circulation of healthy man. Downstream signalling mechanisms,
however, differ between vasodilatation and t-PA release, as well as the vascular bed
being studied.
In the human forearm circulation, high K+ concentrations [Halcox et al, 2001] and
inhibitors of K+ transport across the vascular smooth muscle cell membrane [Honing
et al, 2000; Halcox et al, 2001; Inokuchi et al, 2003; Dwivedi et al, 2005], but not
inhibitors of prostaglandin synthesis [Honing et al, 2000] attenuate bradykinin-
mediated vasodilatation, The effects of inhibition of nitric oxide synthase on
bradykinin-mediated endothelium-dependent vasodilatation in the human forearm
circulation are less clear, previous work reporting either no effect [Brown et al, 2000]
or a modest attenuation of bradykinin-mediated vasodilatation [Cockcroft et al,
1994], Taken together, these findings suggest a role for endothelium-derived
hyperpolarising factor, and potentially, nitric oxide, in mediating the vasodilator
effects of bradykinin in the human forearm circulation. In the coronary circulation in
vivo in man, inhibition of nitric oxide synthase attenuates the bradykinin-mediated
increase in coronary artery diameter and blood flow [Kuga et al, 1995], The
mechanism by which bradykinin induces t-PA release downstream of the B2 kinin
47
Figure8.orea mpl thysmographyset-up.
receptor is less clear. As with bradykinin-mediated vasodilatation, inhibition of nitric
oxide synthase and prostaglandin synthesis does not attenuate the bradykinin-induced
increase in t-PA release in the human forearm circulation in vivo [Brown et al, 2000],
The effects of inhibitors of endothelium-derived hyperpolarising factor on
bradykinin-mediated t-PA release are not known.
Using forearm plethysmography, we have recently demonstrated that combined Bi
and B2 receptor antagonism, but not B2 receptor antagonism alone, causes
vasoconstriction in the forearm circulation of patients with heart failure treated with
ACE inhibition [Witherow et al, 2001]. Besides providing the first evidence of a
potential vasomotor role for the Bi receptor in vivo in man, these results would
suggest that systemic inhibition of vascular kinin receptors would increase blood
pressure and alter systemic haemodyamics in the patients with heart failure treated
with ACE inhibition.
2.1.3 Systemic Haemodynamics
Thermodilution-based continuous cardiac output monitoring, in combination with
pulmonary artery catheterisation has been established as an accurate and
reproducible method for repeatedly assessing systemic haemodynamics in vivo in
man [Ditmyer et al, 1995], This technique employs a thermal filament which
transfers a safe level of heat to the surrounding blood in a pulsed, on-off manner
every 30 seconds (Figure 9). Changes in the temperature of the blood are measured
by a distal rapid-response thermistor in the pulmonary artery. The cardiac output is
then calculated automatically using a modified Stewart-Hamilton equation
[Yelderman, 1993], This technique, combined with intravenous drug administration,
has been used to investigate the haemodynamic effects of systemic drug
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administration in a variety of patient populations including patients with heart failure
[Leslie et al, 2005],
2.2 GENERAL
2.2.1 Ethical Considerations
All studies were performed with the approval of the Lothian Research Ethics
Committee in accordance with the Declaration of Helsinki and with the written
informed consent of each subject.
2.2.2 Umbilical Cord
Human umbilical cord was obtained from women aged 16-40 years undergoing
routine caesarean section following uncomplicated pregnancy.
2.2.3 Patient Preparation
All patients with heart failure abstained from alcohol for 24 hours and from food,
tobacco and caffeine-containing drinks for at least 4 hours before each study. Studies
were performed in a quiet, temperature controlled room maintained at 23-25°C and
diuretics were withheld on days for patient comfort.
2.2.4 Blood Pressure Measurement
Blood pressure was recorded at intervals throughout patient studies using a semi-
automated non-invasive oscillometric sphygmomanometer (Takeda UA 751, Takeda
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Medical Inc, Japan). During forearm venous occlusion plethysmography, blood
pressure was recorded in the non-infused arm.
2.3 UMBILICAL VEIN MYOGRAPHY
2.3.1 Tissue Preparation
Immediately after delivery, 10 cm umbilical cord was excised midway between
placenta and child, and placed in Krebs buffer solution (NaCl 6.954 nmol/L, KC1 4.7
nmol/L, CaCl2 2.5 nmol/L, MgS04 1.17 nmol/L, NaHC03 2 nmol/L, KH2P04 1.18
nmol/L, EDTA 0.027 nmol/L, glucose 5.5 nmol/L; Fisher Scientific UK Ltd,
Loughborough UK). Human umbilical vein was carefully dissected from the cord
and cut into rings of approximately 3 mm width [Sardi et al, 1998; Sardi et al, 1999].
2.3.2 Changes in Vessel Tension
Three hours after delivery, umbilical vein rings were mounted on wire myographs,
suspended in organ baths containing 10 mL Krebs solution and stretched with an
initial tension of 2 g (Multimyograph System 700MO, JP Trading, Denmark). Kreb's
solution was maintained at 37°C and continually bubbled with 95% 02 / 5% C02.
Changes in tension were measured using an isometric transducer (Mac Lab 8, Analog
Digital Instruments Pty Ltd, Australia). Following 60 minutes equilibration, during
which the tension was readjusted at 15 minute intervals, maximal contraction to KC1
(60 mmol/L) was determined on three occasions, interspersed by 15 minute washout
periods to assess tissue viability. Maximal contraction to 60 mmol/L KC1 was
determined on a final occasion at the end of each experiment.
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2.3.3 Data Analysis
Myography data were extracted from Chart™ data files and changes in tension
expressed as a percentage of the maximal contraction to 60 mmol/L KC1 determined
at the end of each experiment.
2.4 IMMUNOHISTOCHEMISTRY
2.4.1 Tissue Preparation
Following contractile studies, human umbilical vein rings were fixed in formalin and
embedded in paraffin wax. Tissue was boiled in 0.01 mol/L sodium citrate (pH 6.0)
for 8 minutes to facilitate antigen retrieval. A haemotoxylin and eosin stain was
performed for each tissue specimen.
2.4.2 I.MMl NOSI AINING
Bj and B2 receptors were immunodetected using diaminobenzidine (DAB)
immunoprecipitation. Non-specific binding sites were blocked with 1:100 donkey
serum followed by 3% H2O2. Tissue sections were then incubated with the primary
affinity purified goat polyclonal antibody specific for human the Bi or B2 kinin
receptor (Santa Cruz Biotechnology, Inc., USA) followed by the secondary antibody
(donkey anti-goat IgG; Santa Cruz Biotechnology Inc, USA) or with the secondary
antibody alone (control). Finally, tissues were treated with a peroxidase-
antiperoxidase strepavidin-biotin conjugating system (Dako K0690) and visualised
by conventional light microscopy using liquid DAB precipitant (Dako K3465).
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2.5 FOREARM VENOUS OCCLUSION PLETHYSMOGRAPHY
2.5.1 BrachialArtery Cannulation
The brachial artery of the non-dominant arm was cannulated under local anaesthesia
using a 27-gauge needle (Cooper's Needle Works Ltd, Birmingham, UK). The
cannula was attached to a 16-gauge epidural catheter (Portex Ltd, Hythe, UK) and
patency maintained by infusion of saline (0.9%: Baxter Healthcare Ltd, Thetford,
UK) via an IVAC PI000 syringe pump (IVAC Ltd, Basingstoke, UK). The total rate
of intra-arterial infusion remained constant throughout all studies at 1 mL/min.
2.5.2 Blood FlowMeasurement
Blood flow was measured in the infused and non-infused forearms by venous
occlusion plethysmography using mercury-in-silastic strain gauges that were applied
to the widest part of the forearm [Webb, 1995]. During measurement periods, the
hands were excluded from the circulation by rapid inflation of the wrist cuffs to a
pressure of 220 mmHg using E20 Rapid Cuff Inflators (D.E. Hokanson Inc,
Washington, USA). Upper arm cuffs were inflated intermittently to 40 mmHg
pressure for 10 seconds in every 15 seconds to achieve venous occlusion and obtain
plethysmography recordings. Analogue voltage output from an EC-4 strain gauge
plethysmograph (D.E. Hokanson) was processed by a MacLab® analogue-to-digital
converter and Chart™ v3.3.8 software (AD Instruments Ltd, Castle Hill, Australia)
and recorded onto a Macintosh Classic II computer (Apple Computers Inc,
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Cupertino, USA). Calibration was achieved using the internal standard of the
plethysmograph.
2.5.3 Data Analysis
Plethysmographic data were extracted from the Chart™ data files and forearm blood
flows were calculated for individual venous occlusion cuff inflations by use of a
template spreadsheet (Excel v5.0; Microsoft). Recordings from the first 60 seconds
after wrist cuff inflation were not used because of the variability in blood flow that
this incurs [Webb, 1995], Usually, the last five flow recordings in each 3 minute
measurement period were calculated and averaged for each arm. Blood flow data was
expressed as the absolute change in blood flow in the infused arm, or where
appropriate, to reduce the variability of blood flow data, the ratio of flows in the two
arms was calculated for each time point: in effect using the non-infused arm as a
contemporaneous control for the infused arm [Benjamin et al, 1995; Webb, 1995],
Percentage changes in the infused forearm blood flow were calculated [Benjamin et
al, 1995; Webb, 1995] as follows:
% Change in blood flow=100 x {It/NIt - It/Nib) / It/NIb
where lb and Nib are the infused and non-infused forearm blood flows at baseline
(time 0) respectively, and It and NIt are the infused and non-infused forearm blood
flows at a given time point respectively.
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2.6 SWAN-GANZ CATHETERISATION
2.6.1 Right Heart Catheterisation
A 9F venous sheath was inserted aseptically under local anaesthesia via the right
femoral vein. Under fluoroscopic screening, a continuous cardiac output
thermodilution Swan-Ganz catheter (Edwards Lifesciences, Irvine, CA, USA) was
positioned in the pulmonary arterial tree.
2.6.2 Systemic Haemodynamic Measurement
Pulmonary arterial pressure, pulmonary arterial wedge pressure and central venous
pressure were recorded using a Hewlett Packard monitor (U78339A, Hewlett
Packard, Andover, MA, USA). Continuous cardiac output was recorded using a
Vigilance monitor (Edwards Lifesciences, Irvine, CA, USA).
2.6.3 Data Analysis
Mean instantaneous cardiac output was determined as the average of three cardiac
output measurements.
2.7 FIBRINOLYTIC PARAMETERS, HAEMATOCRIT AND
NEUROHORMONES
2.7.1 Forearm Venous Sampling
Ten millilitres of blood were withdrawn simultaneously from bilateral 17-gauge
venous cannulae positioned in the antecubital fossa and collected into acidified
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buffered citrate (Biopool Stabilyte, Umea) for t-PA assays and citrate (Monovette,
Sarstedt, Numbrecht) for PAI-1 assays. Samples were kept on ice before being
centrifuged at 2,000 g for 30 minutes at +4°C. Platelet-free supernatant was decanted
and stored at -70°C before assay.
2.7.2 Systemic Venous Sampling
Thirty millilitres of blood was collected from the side arm of the venous sheath into
lithium heparin for determination of plasma ACE activity and 0.45%
o-phenanthroline/4.65% disodium ethylene diamine tetraacetic acid for
determination of plasma angiotensin II concentrations. Blood samples were collected
on ice, centrifuged immediately and the resulting supernatant stored at -70°C until
assayed.
2.7.3 Plasma Fibrinolytic Parameter Assays
Plasma PAI-1 and t-PA antigen concentrations were determined using an enzyme-
linked immunosorbent assay; Coaliza® PAI-1 [Declerck and Collen, 1990] and
Coaliza®t-PA [Booth et al, 1987] (Chromogenix AB, Molndal, Sweden) respectively
and t-PA activity, by a photometric method, Coaset® t-PA [Gram et al, 1987]
(Chromogenix AB). The intra-assay coefficients of variation were 5.5 and 2.4% for
t-PA antigen and activity respectively and 7.0% for PAI-1 antigen. The inter-assay
coefficients of variation were 4.0, 4.0 and 7.3% respectively. The sensitivities of the
assays were 0.5 ng/rnL, 0.1 IU/mL and 2.5 ng/mL respectively.
57
2.7.4 Plasma Haematocrit
Haematocrit was determined by capillary tube centrifugation of blood anticoagulated
by ethylene diamine tetraacetic acid.
2.7.5 Plasma Neurohormone Assays
Plasma ACE activity was determined using colourimetric spectrophotometry (Sigma
Diagnostics, St Louis, MO, USA) [Holmquist et al, 1979]. Following extraction
using Bond Elut® columns (Varian, Harbor City, CA, USA), plasma angiotensin II
(Diasorin, Stillwater, MN, USA) concentrations were determined by
radioimmunoassay [Morton et al, 1985],
2.7.6 Data Analysis
Estimated net release of t-PA antigen and activity were defined as the product of the
infused forearm plasma flow (based on the mean haematocrit and forearm blood
flow) and the concentration difference between the infused ([t-PA]inf) and non-
infused arms ([t-PA]Non-inf) [Newby et al, 1997b; Newby et al, 1999].
Estimated net forearm t-PA release=FBF x {1-Hct} x {[t-PA]inf- [t-PA]Non-inf}-
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CHAPTER 3
VASOMOTOR EFFECTS OF KININ RECEPTOR AGONISTS AND
ANTAGONISTS IN ISOLATED HUMAN UMBILICAL VEIN
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3.1 SUMMARY
The current study was performed to confirm the biological activity of custom-made
selective peptidic kinin receptor agonists and antagonists in human tissue in vitro
prior to their use in clinical studies in vivo. Following pre-incubation with captopril,
contraction of human umbilical vein rings to increasing concentrations of Lys-des-
Arg9-bradykinin (Bi receptor agonist) or bradykinin (B2 receptor agonist) in the
presence or absence of Lys-[Leu8]-des-Arg9-bradykinin (Bi antagonist), HOE-140
(B2 antagonist) or B9340 (combined B1/B2 antagonist) was measured using
myography. Lys-des-Arg9-bradykinin and bradykinin caused dose-dependent
O Q
constriction of human umbilical vein rings (p<0.001 for both). Lys-[Leu ]-des-Arg -
bradykinin and B9340 caused an approximate 10-fold rightwards shift, whilst HOE-
140 caused a modest leftwards shift in the dose response curve for Lys-des-Arg9-
bradykinin (p<0.001, p<0.001 and p<0.05 respectively). In contrast, HOE-140 and
B9340, but not Lys-[Leu8]-des-Arg9-bradykinin, caused a rightwards shift in the dose
response curve for bradykinin (p<0.001, p<0.01 and p=not significant respectively).
These findings confirm the biological activity of the custom manufactured
preparations of peptidic kinin receptor agonists and antagonists in human tissue in
vitro. In addition, augmentation of Bi mediated responses in the presence of a B2




First proposed in 1977 [Regoli et al, 1977], subsequent work has confirmed the
existence of two human kinin receptor subtypes, Bi and B2. With the advent of
molecular cloning, the primary structure of both kinin receptors has been established,
identifying them as members of the G-protein superfamily characterised by seven
transmembrane a helices [McEachern et al, 1991; Menke et al, 1994],
Functional expression of vascular kinin receptors has traditionally been characterised
by smooth muscle responses to selective kinin receptor agonists in organ bath
preparations [Regoli et al, 1977; Drummond and Cocks, 1995a; Gobeil et al, 1996;
Sardi et al, 1998; Sardi et al, 1999]. Using this technique, Bi and B2 receptor
mediated responses have been identified in tissues from a wide variety of vascular
sites and species, including human umbilical vein [Regoli et al, 1977; Gobeil et al,
1996; Sardi et al, 1998; Sardi et al, 1999] and coronary artery [Drummond and
Cocks, 1995b], Human umbilical vein examined in this way exhibits constitutive B2
receptor mediated responses, as well as Bi receptor mediated responses, which are
absent initially but develop in magnitude as a function of the in vitro incubation time
[Bouthillier et al, 1987; Gobeil et al, 1996; Sardi et al, 1998; Sardi et al, 1999]. These
responses can also be invoked by pre-incubation of tissue with bacterial
lipopolysaccharide or inflammatory cytokines, such as interleukin-ip [Sardi et al,
1998] and tumour necrosis factor-a [Sardi et al, 1999].
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Bradykinin has high affinity and selectivity for the human B2 receptor and is the
principal ligand in plasma. Removal of the C-terminal arginine from bradykinin and
related peptides is a key determinant of affinity at the human B] receptor. Although
des-Arg9-bradykinin is the most abundant Bi agonist present in plasma, it has only
modest affinity for the human Bi receptor and retains some activity at the human B2
receptor, being only 100-fold more selective for the human Bj receptor [Marceau et
al, 1998; Leeb-Lundberg et al, 2005], In contrast, Lys-des-Arg9-bradykinin, a tissue-
based metabolite of kallidin, is the only naturally occurring kinin sequence with
subnanomolar affinity at the human Bi receptor. Indeed, Lys-des-Arg9-bradykinin
has -1000-fold greater affinity for the Bi receptor than des-Arg9-bradykinin, and is
inactive at the B2 receptor in man [Gobeil et al, 1996; Marceau et al, 1998;
Christiansen et al, 2002; Leeb-Lundberg et al, 2005].
Development of peptidic Bi receptor antagonists began in the 1970s with
8 9 • •modification of the bradykinin sequence to produce [Leu ]-des-Arg -bradykinin
[Regoli et al, 1977; Stewart et al, 1997]. Although highly selective for the human Bi
O Q
receptor, [Leu ]-des-Arg -bradykinin retains some partial agonist activity [Marceau
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et al, 1998]. Further modification led to the development of Lys-[Leu ]-des-Arg -
bradykinin, a synthetic peptide with potent selective inhibitory activity at the human
Bj receptor [Marceau et al, 1998; Deblois et al, 2001]. Peptide antagonists for the B2
receptor were developed later. Of these, icatibant, or HOE-140, is a synthetic peptide
antagonist with high affinity and selectivity at the human B2 receptor that has been
used most extensively to investigate B2 kinin receptor physiology in animal models
and in man in vivo. In contrast, B9340 is a synthetic peptide sequence with
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significant antagonist activity at both the Bi and B2 kinin receptor [Stewart et al,
1997],
We obtained bradykinin, Lys-des-Arg9-bradykinin, Lys-[Leu8]-des-Arg9-bradykinin,
HOE-140 and B9340 custom manufactured for use in clinical studies. Using organ
bath myography, the aims of this study were to confirm the biological activity of




Human umbilical cord was obtained from women aged 16-40 years undergoing
routine caesarean section following uncomplicated pregnancy with the approval of
the Local Research Ethics Committee, in accordance with the Declaration of
Helsinki and with the written informed consent of each subject.
3.3.2 Drugs
Captopril (Sigma Pharmaceuticals, St Louis, MO) and pharmaceutical grade Lys-
des-Arg9-bradykinin (Clinalfa AG, Laufelfingen, Switzerland), bradykinin (Clinalfa),
Lys-[Leu8]-des-Arg9-bradykinin (Clinalfa), HOE-140 (Clinalfa) and B9340
(Clinalfa) were dissolved in physiological saline on the day of study. The doses of
peptides were chosen based on the results of affinity binding studies [Regoli and
Barabe, 1980 Marceau et al, 1998; Leeb-Lundberg et al, 2005] and data from
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previous human umbilical vein myography studies [Gobeil et al, 1996; Sardi et al,
1998; Sardi et al, 1999],
3.3.3 Study Design
Tissue rings were mounted on the myograph, allowed to equilibrate for 60 minutes
and maximum contraction to KC1 (60 mmol/L) determined. Tissue rings were then
incubated with captopril (1 pmol/L) 30 minutes prior to performing cumulative dose
responses to bradykinin (10~H - 10"6mol/L) and Lys-des-Arg9-bradykinin (10~n - 10~6
O Q
mol/L) in the presence or absence of Lys-[Leu ]-des-Arg -bradykinin (1 pmol/L),
HOE-140 (1 pmol/L) or B9340 (1 pmol/L). Peptide antagonists were applied
10 minutes before agonists to ensure that equilibrium was obtained. Maximal
contraction to 60 mmol/L KC1 was determined on a final occasion at the end of each
experiment. A single concentration curve for bradykinin and Lys-des-Arg9-
bradykinin was obtained for each ring, and experiments were performed in parallel
with rings from the same tissue.
3.3.4 Immunohistochemistry
Following contractile studies, human umbilical vein rings were fixed in formalin and
embedded in paraffin wax. A haemotoxylin and eosin stain was performed for each
tissue section and Bi and B2 receptors were immunodetected using DAB
immunoprecipitation.
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3.3.5 Data Analysis and Statistics
Human umbilical vein responses are expressed as a percentage of the maximal
contraction to 60 mmol/L KC1 obtained at the end of each experiment. Data were
examined by two-way analysis of variance (ANOVA) with repeated measures using
GraphPad PRISM (GraphPad). All results are expressed as mean ± standard error of
the mean. Statistical significance was taken at the 5% level.
3.4 RESULTS
Immunohistochemistry confirmed intense immunolabelling of both Bi and B2
receptors on human umbilical vein (Figure 10). Consistent with previous work
[Gobeil et al 1996; Sardi et al, 1998], bradykinin and Lys-des-Arg9-bradykinin
caused dose-dependent constriction of human umbilical vein rings (Figure 11;
o q
p<0.001 for both). Lys-[Leu ]-des-Arg -bradykinin and B9340 caused an
approximate 10-fold rightwards shift and HOE-140 caused a modest leftwards
shift in the dose response curve for Lys-des-Arg9-bradykinin (Figure 11a;
p<0.001, p<0.001 and p<0.05 respectively). In contrast, HOE-140 and B9340,
o q
but not Lys-[Leu ]-des-Arg -bradykinin, caused a rightwards shift in the dose
response curve for bradykinin (Figure lib; p<0.001, p<0.001 and p=not
significant respectively).
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Figure 10. Human umbilical vein ring stained with haemotoxylin and eosin (a). Immunolabelling
(DAB) of Bi (b) and B2 (d) kinin receptors on smooth muscle cells of human umbilical vein rings and
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3.5 DISCUSSION
We have demonstrated both histologically and functionally that Bj and B2 kinin
receptors are present in human umbilical vein. Using myography of human umbilical
vein rings, we have confirmed that the vasomotor effects of the Bi agonist, Lys-des-
Arg9-bradykinin, and the B2 agonist, bradykinin, are selectively attenuated by the Bi
o Q
kinin receptor antagonist, Lys-[Leu ]-des-Arg -bradykinin, and the B2 receptor
antagonist, HOE-140, respectively. In addition, the combined B1/B2 receptor
antagonist, B9340, significantly attenuated the vasomotor activity of both Lys-des-
Arg9-bradykinin and bradykinin confirming blockade at both the Bi and B2 receptor.
These findings confirm that clinical grade preparations of kinin and kinin-related
peptides are biologically active in human tissue.
Human umbilical vein cut into rings has greater mechanical activity than when cut
longitudinally due to the circular arrangement of the outer layer of smooth muscle
[Altura et al, 1972]. Previous studies have demonstrated that myography of human
umbilical vein is an appropriate model with which to assess vascular kinin receptor
function [Gobeil et al, 1996; Sardi et al, 1998; Sardi et al, 1999], In the present
studies, as with previous work, the biological activity of peptides was assessed in the
presence of captopril to prevent degradation by ACE [Gobeil et al, 1996; Sardi et al,
1998; Sardi et al, 1999]. The concentration-response curves obtained for bradykinin
and Lys-des-Arg9-bradykinin were comparable with data from these previous studies
[Gobeil et al, 1996; Sardi et al, 1998; Sardi et al, 1999] and confirm efficacy at
concentrations predicted to be achieved in the infused human forearm circulation.
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The vasomotor effects of bradykinin have been studied in arteries and veins from a
variety of different human tissues. In man, bradykinin is relaxant in all vessels except
umbilical vein and artery although the mechanisms responsible for this remain
unclear [Regoli and Barabe, 1980], It has been suggested that stimulation of kinin
receptors expressed on vascular smooth muscle leads to vasoconstriction, whilst
stimulation of endothelial kinin receptors results in vasodilatation. Differences in
downstream signalling pathways may also account for the contrasting vasomotor
responses.
The Bi and B2 kinin receptors are coupled to similar G-protein subtypes and share
the same intracellular signalling pathways [Leeb-Lundberg et al, 2005]. It has been
suggested that cross-talk may exist between the two receptor subtypes [Duka et al,
2001; Barki-Harrington et al, 2003]. In transgenic mice lacking the B2 kinin receptor,
for example, the Bi receptor is upregulated and assumes vascular functions normally
associated with the B2 receptor [Duka et al, 2001], Our findings that the B2 receptor
antagonist, HOE-140, augments the vasomotor responses to the Bi agonist, Lys-des-
Arg9-bradykinin, in human umbilical vein in vitro are in keeping with this
hypothesis.
In summary, we have confirmed that Lys-des-Arg9-bradykinin and bradykinin are
potent vasoconstrictors in human umbilical vein in vitro and these effects are blocked
o q ...
by the selective kinin receptor antagonists, Lys-[Leu ]-des-Arg -bradykinin and
HOE-140 respectively, and in both cases by the combined receptor antagonist,
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B9340. Our findings confirm the biological activity of clinical grade peptidic kinin
receptor agonists and antagonists in human vascular tissue.
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CHAPTER 4
BRADYKININ CONTRIBUTES TO THE SYSTEMIC HAEMODYNAMIC
EFFECTS OF CHRONIC ANGIOTENSIN-CONVERTING ENZYME
INHIBITION IN PATIENTS WITH HEART FAILURE
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4.1 SUMMARY
Bradykinin is an endogenous vasodilator that may contribute to the systemic effects
of ACE inhibitor therapy. Using B9340, a bradykinin receptor antagonist, we
determined the contribution of bradykinin to the systemic haemodynamic effects of
long-term ACE inhibition in patients with chronic heart failure. Fourteen patients
with heart failure received enalapril (10 mg twice daily) or losartan (50 mg twice
daily) in a randomised double-blind cross-over trial. After 6 weeks treatment,
patients underwent right heart catheterisation and were randomised to an intravenous
infusion of B9340 (2-20 pg/kg/min) or saline placebo. Following B9340 infusion in
patients treated with enalapril, mean arterial pressure (+5.2 mmHg), systemic
vascular resistance (+315 dynes.s/cm5), pulmonary arterial wedge pressure
(-1.4 mmHg) and mean pulmonary arterial pressure (-1.3 mmHg) were greater
compared to losartan (p<0.005, p=0.07, p<0.0001 and p<0.05 respectively) or
placebo infusion (p<0.005 for all). There was a reduction in cardiac output after
B9340 with enalapril compared to placebo (p<0.001) but not losartan. We have
demonstrated that bradykinin contributes to the systemic haemodynamic effects of
long-term ACE inhibition in patients with heart failure. Our findings may explain the
apparent clinical differences between ACE inhibitors and angiotensin receptor
blockers in the treatment of heart failure.
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4.2 INTRODUCTION
Activation of the renin-angiotensin-aldosterone system plays a key role in the
pathogenesis of chronic heart failure, leading to salt and water retention and
peripheral vasoconstriction. Inhibitors of ACE reduce peripheral vascular tone and
systemic arterial pressure [Powers et al, 1982] and improve symptoms and survival
in patients with chronic heart failure [CONSENSUS, 1987], Although previously
attributed to a reduction in angiotensin-mediated vasoconstriction, recent data have
indicated that the haemodynamic changes associated with ACE inhibitor therapy
may be due, at least in part, to the inhibition of bradykinin metabolism.
The bradykinin metabolising properties of ACE (kininase II) were first described in
1967 [Erdos and Yang, 1967]. Indeed, ACE has greater affinity for bradykinin than
for angiotensin I [Jaspard et al, 1993] and is the principal enzyme responsible for the
rapid turnover of bradykinin (plasma half-life -15 seconds) [Bonner et al, 1990],
This rapid metabolism makes accurate measurement of bradykinin difficult, although
elevated plasma bradykinin concentrations have been reported in the presence of
ACE inhibition [Pellacani et al, 1994], Bradykinin is a powerful endothelium-
dependent vasodilator and, at a functional level, inhibition of ACE potentiates the
action of exogenous bradykinin in the human forearm and coronary circulations
[Benjamin et al, 1989; Kuga et al, 1997; Witherow et al, 2002],
There are two principal kinin receptor subtypes in man, B i and B2 [Leeb-Lundberg et
al, 2005], The endothelial B2 receptor is constitutively expressed and mediates the
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vasodilator and pro-fibrinolytic effects of bradykinin [Cockcroft et al, 1994; Brown
et al, 2000], The vascular B] receptor is normally expressed very weakly but is
markedly upregulated in the presence of inflammation, cardiovascular disease states
[McLean et al, 2000b] and ACE inhibition [Nwator and Whalley, 1989; Marin-
Castano et al, 2002], where it also mediates vasodilatation [Drummond and Cocks,
1995b],
The selective kinin receptor antagonists, HOE-140 (icatibant) and B9340, are
synthetic peptide analogues of bradykinin with different inhibitory activities at the
specific kinin receptor subtypes. HOE-140 acts solely at the B2 receptor, whereas
B9340 blocks kinin activity mediated via both Bi and B2 receptors [Stewart et al,
1997], Several investigators have reported that intravenous HOE-140 attenuates the
vasodepressor response associated with acute ACE inhibition, both in healthy
volunteers and in hypertensive patients [Gainer et al, 1998; Squire et al, 2000], In
contrast, B9340, but not HOE-140, induced vasoconstriction in the forearm
circulation of patients with heart failure treated with chronic ACE inhibitor therapy
[Davie et al, 1999; Witherow et al, 2001], Besides implicating bradykinin in the
haemodynamic changes associated with ACE inhibition, these data raise the
possibility of a role for the Bi receptor in patients with chronic heart failure
[Witherow et al, 2001],
The aims of the present study were to demonstrate that the kinin receptor antagonist,
B9340, inhibits bradykinin activity in the systemic circulation and to determine
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whether endogenous bradykinin contributes to the haemodynamic effects of long-
term ACE inhibition in patients with chronic symptomatic heart failure.
4.3 METHODS
4.3.1 Patients
Fourteen patients with stable New York Heart Association (NYHA) class II-III
chronic heart failure and objective evidence of left ventricular impairment (left
ventricular ejection fraction <40%, shortening fraction <20%, or left ventricular end-
diastolic diameter >5.5 cm) were enrolled into the study. Patients were included only
if they had been established on maximally tolerated ACE inhibitor therapy for at
least 6 months. Patients were excluded if they had significant valvular heart disease,
renal or hepatic failure, or had suffered previous malignant ventricular arrhythmias.
4.3.2 Drugs
B9340 (molecular weight 1318.6) is a synthetic peptide antagonist of bradykinin
with potent inhibitory activity at both the Bi and B2 receptors (pIC50 in vitro of 8.1
and 9.8, respectively) [Stewart et al, 1997], The doses of B9340 and bradykinin were
chosen based on the results of dose ranging studies performed in the forearm and
systemic circulations of healthy volunteers [Witherow et al, 2003; Cruden et al,
2004] (Figure 12). Pharmaceutical grade B9340 was supplied by Clinalfa AG
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4.3.3 Study Design
Following initial screening, patients received enalapril 10 mg [CONSENSUS, 1987]
or losartan 50 mg [Pitt et al, 2000], both twice daily, in place of their usual ACE
inhibitor in a randomised double-blind cross-over trial. After 6 weeks of each
treatment, subjects attended fasted at 8.00 a.m. and underwent right heart
catheterisation. On the morning of each visit, oral study medication was administered
at 7.00 a.m. to achieve peak plasma concentrations of the active metabolites,
enalaprilat or E-3174 respectively, during B9340 or placebo infusion
(10-11.00 a.m.). Diuretics were withheld on the morning of each study for patient
comfort.
4.3.4 Haemodynamic Study Protocol
Following a 30 minute infusion of 50 mL saline, patients received an intravenous
infusion of B9340 at 2, 6 and 20 pg/kg/min for 15 minutes at each dose or saline
placebo (75 mL) in a randomised, double-blind manner. The randomisation was
weighted such that ten patients on enalapril received B9340, ten patients on losartan
received B9340 and six patients on either enalapril or losartan received placebo
(Figure 13). Haemodynamic measurements were recorded at -40, -30, -10, 0
(baseline), +7, +15, +22, +30, +37, +45, +60, +75, +90 and +105 minutes during
each study. Venous blood was collected at 0 (baseline), +45 and +105 minutes for
determination of plasma ACE activity and plasma angiotensin II concentrations.
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4.3.5 Laboratory Analysis
Blood samples were collected on ice, centrifuged immediately, and the resulting
supernatant stored at -70°C until assayed. Plasma ACE activity was determined using
colourimetric spectrophotometry (SIGMA Diagnostics, St Louis, Mo) [Holmquist et
al, 1979]. After extraction using Bond Elut columns (Varian; Elarbor City, Calif),
plasma angiotensin II (Diasorin, Stillwater, Minn) concentrations were determined
by radioimmunoassay [Morton and Webb, 1985],
4.3.6 Data Analysis and Statistics
Data are expressed as mean ± standard error of the mean. Haemodynamic parameters
were assessed over time as absolute change from baseline (0 minutes) using one-way
ANOVA with repeated measures. Comparisons between treatment groups were made
using two-way ANOVA for which the within-subject variables were drug and time.
Plasma neurohormone concentrations were compared at baseline using an unpaired
/-test. Statistical significance was taken at the 5% level.
4.4 RESULTS
Following the first visit, one patient withdrew due to worsening heart failure
unrelated to treatment and was replaced. There were no significant differences in
patient characteristics or baseline haemodynamic parameters between treatment
groups (Table 3).
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Age yrs (range) 62 (45 - 75) 63 (45 - 78) 66 (60 - 73)
Gender (male/female) 8/2 9/1 5 / 1
Diagnosis (IHD/DCM) 9/1 8/2 5/1
NYHA class (II/III) 8/2 6/4 3/3
Ejection fraction (%) 28 ±3 28 ±3 31 ±2
Body mass index 26 ± 1 26 ± 1 25 ±2
Concomitant medications
Aspirin 8 8 6
Diuretic 9 8 5
Beta-blocker 7 6 3
Statin 7 6 5
Nitrate 3 3 3
Digoxin 2 1 3
Calcium antagonist 1 2 1
Spironolactone 0 1 1
Baseline haemodynamics
Heart rate (beats/min) 62 (3) 62(4) 61 (3)
MAP (mmHg) 81(4) 83(4) 83 (3)
SVR (dynes.s/cm5) 1228(116) 1194(110) 1443 (80)
Cardiac output (L/min) 5.4 (0.4) 5.6 (0.5) 4.7 (0.2)
CVP (mmHg) 1 (1) 1 (1) 1 (1)
MPAP (mmHg) 15(2) 18(2) 15(2)
PAWP (mmHg) 5(1) 9(2) 7(1)
Data are expressed as number of patients or mean ± SEM. IHD, ischaemic heart disease; DCM, idiopathic
dilated cardiomyopathy; NYHA, New York Heart Association; MAP, mean arterial pressure; SVR,
systemic vascular resistance; CVP central venous pressure; MPAP, mean pulmonary arterial pressure;
PAWP, pulmonary arterial wedge pressure.
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4.4.1 PlasmaNeurohormones
Plasma ACE activity (13.2 ± 2.4 versus 38.8 ± 4.8 units/L; pO.OOOl) and plasma
angiotensin II concentrations (3.5 ± 0.5 versus 12.3 ± 2.3 pg/mL; p<0.005) at
baseline on the morning of haemodynamic studies were significantly lower in
patients treated with enalapril compared to losartan respectively (Figure 14). There
were no significant changes in plasma ACE activity or angiotensin II concentrations
during or following B9340 or placebo infusion (Table 4).
4.4.2 Haemodynamic Parameters
4.4.2.1 Mean Arterial Pressure and Heart Rate
There were no significant changes in heart rate or mean arterial pressure during
placebo infusion or following losartan therapy. Mean arterial pressure increased after
administration of B9340 in patients treated with enalapril (p<0.005; Figure 15)
although there was no significant change in heart rate. This pressor effect was greater
in patients treated with enalapril than those given losartan therapy or placebo
infusion (p<0.005 and pO.OOOl respectively; Figure 15).
4.4.2.2 Cardiac Output and Systemic Vascular Resistance
There were no significant changes in cardiac output or systemic vascular resistance
during placebo infusion or following losartan therapy. In patients treated with
enalapril receiving B9340, there was a trend towards an increase in systemic vascular
resistance (p=O.08) but no change in cardiac output (Figure 15). Compared to
placebo infusion, there was an increase in systemic vascular resistance and a fall in
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Figure 15. Changes in (a) mean arterial pressure (MAP), (b) systemic vascular resistance (SVR) and (c)
cardiac output (CO) following intravenous infusion of saline placebo (crosses) or B9340 (2-20
pg/kg/min) in patients with chronic heart failure treated with enalapril (closed squares) or losartan (open
circles).
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p<0.001 respectively; Figure 15). There was a trend towards an increase in systemic
vascular resistance in the enalapril treated group compared to those receiving
losartan (p=0.07; Figure 15).
4.4.2.3 Central Pressures
Central venous pressure, pulmonary arterial wedge pressure and mean pulmonary
arterial pressure all fell significantly over time during placebo infusion (p<0.05 for
all; Figure 16). Compared to losartan therapy or placebo infusion, B9340 attenuated
the fall in pulmonary arterial wedge pressure (pO.OOOl for both) and mean
pulmonary arterial pressure (p<0.05 and p=0.005 respectively) in patients treated
with enalapril (Figure 16). There were no significant differences in the reductions of
central venous pressure between treatment groups (Figure 16).
4.4.3 Adverse Events
There were no major drug-related adverse events reported. One patient reported mild
self-limiting diarrhoea following B9340 infusion.
4.5 DISCUSSION
We have demonstrated that intravenous administration of B9340, a selective peptidic
antagonist of bradykinin receptors, has a significant pressor effect in patients with
chronic heart failure maintained on long-term ACE inhibitor but not angiotensin
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Figure 16. Changes in (a) pulmonary arterial wedge pressure (PAWP), (b) mean pulmonary arterial
pressure (MPAP) and (c) central venous pressure (CVP) following intravenous infusion of saline placebo
(crosses) or B9340 (2-20 ug/kg/min) in patients with chronic heart failure treated with enalapril (closed
squares) or losartan (open circles).
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bradykinin contributes to the hypotensive effects of chronic ACE inhibitor therapy in
patients with heart failure.
We have previously shown that B9340 causes vasoconstriction in the forearm
circulation in patients with heart failure treated with chronic ACE inhibitor therapy
[Witherow et al, 2001]. The results of the present study confirm that these effects are
important in the systemic circulation. This is consistent with published data
demonstrating that the bradykinin receptor antagonist, HOE-140, attenuates the acute
vasodepressor response to ACE inhibition. Gainer and colleagues demonstrated that
in salt deplete healthy volunteers as well as hypertensive subjects, a systemic
infusion of HOE-140 attenuated the hypotensive response to a single dose of
captopril [Gainer et al, 1998], The reduction in blood pressure observed following
co-administration of HOE-140 and captopril was similar to that seen with the
angiotensin receptor blocker, losartan [Gainer et al, 1998]. As the authors point out,
previous studies have demonstrated that the peak hypotensive responses to captopril
and losartan occur 1 and 4 hours respectively after drug administration [Gainer et al,
1998],
It has been suggested that these differences could account for the observed
differences in the blood pressure response [Gainer et al, 1998], To overcome this
potential methodological difficulty, we chose to compare the ACE inhibitor,
enalapril, at a dose previously shown to reduce mortality in patients with heart failure
[CONSENSUS, 1987] with the angiotensin receptor antagonist, losartan,
administered at the maximum daily dose. Both these agents have long-acting active
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metabolites, enalaprilat and E-3174 respectively, achieving peak plasma
concentrations 3-4 hours post ingestion that coincided with systemic intravenous
administration of B9340 or placebo [Abrams et al, 1984; Ohtawa et al, 1993]. It
should also be recognised that we have assessed the effects of kinin receptor
blockade in patients maintained on long-term ACE inhibitor therapy rather than the
acute effects of a single oral dose. Moreover, patients with heart failure maintained
on chronic ACE inhibitor therapy may upregulate vascular Bj kinin receptor
expression [Nwator and Whalley, 1989; Witherow et al, 2001; Marin-Castano et al,
2002] and we therefore used a combined Bj and B2 receptor antagonist to characterise
more precisely the role of bradykinin.
It has been argued [Schiffrin, 2002] that angiotensin receptor blockade might
potentially be more effective at blocking the detrimental effects of angiotensin II
than ACE inhibition because in a substantial proportion of patients treated with
chronic ACE inhibition, plasma angiotensin II concentrations rise over time returning
towards pre-treatment values [MacFadyen et al, 1999], This "ACE escape" is thought
to be due to angiotensin II formation by non-ACE dependent pathways and may be
associated with a poorer prognosis [Roig et al, 2000; Petrie et al, 2001]. However,
clinical evidence that angiotensin receptor blockers have superior efficacy to ACE
inhibitor therapy has proved elusive. In contrast, recent trials have confirmed that the
therapeutic benefits ofACE inhibitors and angiotensin receptor blockers are additive:
combination therapy improving symptoms and cardiovascular mortality in patients
with heart failure when compared to ACE inhibition alone [Cohn and Tognoni, 2001;
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McMurray et al, 2003]. Our findings may help to explain the additive benefits of
combined ACE inhibition and angiotensin receptor blockade.
Large-scale clinical trials have demonstrated that ACE inhibitors not only improve
survival but reduce the incidence ofmyocardial ischaemia [Flather et al, 2000], This
may be explained, in part, by the observation that ACE inhibition improves the
fibrinolytic balance in patients with heart failure and ischaemic heart disease [Wright
et al, 1994], Bradykinin is not only a potent vasodilator but is intimately involved
with the coagulation and fibrinolytic cascades. Indeed, it is a powerful mediator of
endogenous fibrinolysis through the release of endothelium-derived t-PA [Brown et
al, 2000; Witherow et al, 2002; Pretorius et al, 2003], In patients with heart failure,
chronic ACE inhibition markedly augments local bradykinin-mediated release of
t-PA [Witherow et al, 2002], Thus, potentiation of the other vascular actions of
bradykinin may also contribute to the clinical benefits ofACE inhibitor therapy.
In patients treated with losartan, there was a small but significant increase in mean
arterial pressure and systemic vascular resistance following B9340 infusion
compared to placebo. This may have reflected the significant protein load associated
with B9340 infusion and a protein-based placebo, such as albumin, may have been a
more appropriate control. There are data indicating that bradykinin may contribute to
the vascular effects of angiotensin receptor blockers. In transgenic mice
overexpressing the AT2 receptor, angiotensin II causes vasodilatation that is
attenuated by HOE-140 [Tsutsumi et al, 1999] and in man, HOE-140 inhibits the
improvement in flow-mediated vasodilatation associated with the angiotensin
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receptor blocker, candesartan [Hornig et al, 2003]. Finally, the findings are consistent
with the possibility that bradykinin also contributes to the maintenance of blood
pressure and vascular tone in patients with heart failure independently ofACE.
In summary, we have shown that in patients with chronic heart failure, systemic
infusion of the combined kinin receptor antagonist, B9340, attenuates the
vasodepressor effects associated with long-term enalapril therapy when compared to
treatment with the angiotensin receptor blocker, losartan. We conclude that, in
patients with chronic symptomatic heart failure, bradykinin contributes to the
systemic haemodynamic effects associated with long-term ACE inhibitor therapy.
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CHAPTER 5
NEUTRAL ENDOPEPTIDASE INHIBITION AUGMENTS THE VASCULAR
ACTIONS OF BRADYKININ IN PATIENTS TREATED WITH
ANGIOTENSIN-CONVERTING ENZYME INHIBITOR THERAPY
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5.1 SUMMARY
Angiotensin-converting enzyme and neutral endopeptidase (EC 3.4.24.11;
neprilysin) are metallopeptidases present on the endothelium that metabolise
bradykinin. Inhibitors of ACE potentiate bradykinin-mediated vasodilatation and
endothelial t-PA release. Combined ACE and NEP inhibition may have additional
beneficial cardiovascular effects mediated through potentiation of bradykinin. We
investigated the effects of local NEP inhibition on the vascular actions of bradykinin
in patients with heart failure maintained on chronic ACE inhibition. Ten patients
received an intrabrachial infusion of thiorphan (30 nmol/min), a NEP inhibitor, in a
randomised double-blind placebo-controlled cross-over trial. Thiorphan was co-
infused with Lys-des-Arg9-bradykinin (1-10 nmol/min), bradykinin (30-300
pmol/min), atrial natriuretic peptide (10-100 pmol/min) and sodium nitroprusside (2-
8 pg/min). Bradykinin, atrial natriuretic peptide and sodium nitroprusside caused
dose-dependent vasodilatation (peak blood flow 14.4 ± 2.2, 3.6 ± 0.6 and
8.6 ± 1.3 mL/lOOmL/min respectively; p<0.0001). Bradykinin caused dose-
dependent increases in t-PA antigen and activity (peak concentration
31.8 ± 3.4 ng/mL and 21.9 ± 7.6 IU/mL respectively; p<0.001) and estimated antigen
and activity release (peak release 152 ± 46 ng/lOOmL/min and
154 ± 22 IU/lOOmL/min respectively; p<0.005). Compared to placebo, thiorphan
augmented bradykinin-mediated vasodilatation (1.4-fold; p<0.0001) and net t-PA
release (1.5-fold; p<0.005). We have demonstrated that NEP contributes to the
metabolism of bradykinin in patients with heart failure maintained on ACE inhibitor
therapy. Our findings may explain some of the clinical effects of combined ACE and
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NEP inhibition, including the greater vasodepressor effect observed with combined
therapy when compared to ACE inhibition alone.
5.2 INTRODUCTION
Bradykinin is a potent endothelium-dependent vasodilator peptide released at sites of
inflammation and coagulation. Apart from vasodilatation, it also stimulates
endothelial release of the pro-lytic factor, t-PA, and these effects are mediated by the
constitutively expressed B2 receptor [Brown et al, 2000; Witherow et al, 2002],
Removal of the C-terminal arginine from bradykinin results in the formation of des-
Arg9-bradykinin, the principal ligand for the Bi kinin receptor in plasma [Marceau et
al, 1998]. However, the most potent endogenous ligand for the Bi kinin receptor is
Lys-des-Arg9-bradykinin [Marceau et al, 1998], The vascular Bi receptor is normally
expressed very weakly but is markedly upregulated in the presence of inflammation
[McLean et al, 1999; Deblois et al, 2001], cardiovascular disease [McLean et al,
2000b] and ACE inhibition [Nwator and Whalley, 1989; Marin-Castano et al, 2002],
where it also mediates vasodilatation [Marceau et al, 1998],
ACE is the principal enzyme responsible for the rapid turnover of bradykinin
(plasma half-life -15 seconds) and its metabolites [Marceau et al, 1998]. It has been
widely established that inhibitors of ACE improve morbidity and mortality in
patients with heart failure [CONSENSUS, 1987] and these benefits may be due, at
least in part, to the inhibition of bradykinin metabolism [Gainer et al, 1998;
Witherow et al, 2001], Inhibition of ACE increases the plasma half-lives of
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bradykinin and des-Arg9-bradykinin approximately 9- and 2-fold respectively [Cyr et
al, 2001] and, at a functional level, potentiates the vascular actions of bradykinin in
the human forearm [Benjamin et al, 1989; Witherow et al, 2002] and coronary [Kuga
et al, 1997] circulations. Moreover, bradykinin antagonism causes vasoconstriction
[Witherow et al, 2001] and attenuates the fall in blood pressure [Gainer et al, 1998]
in patients treated with ACE inhibitor therapy.
Neutral endopeptidase (EC 3.4.24.11; neprilysin) is a membrane-bound
metallopeptidase that co-localises with ACE and metabolises a number of vasodilator
and vasoconstrictor peptides, including atrial natriuretic peptide, substance P,
endothelin-1 and bradykinin [Roques et al, 1993]. Expression ofNEP is upregulated
in patients with heart failure [Fielitz et al, 2002; Knecht et al, 2002] and, in the
presence of ACE inhibition, the contribution of NEP to bradykinin metabolism is
increased [Dumoulin et al, 1998]. Inhibition of NEP potentiates the half-life of
bradykinin [Graf et al, 1993] and augments bradykinin-mediated vasodilatation in
vitro [Krassoi et al, 2003]. It is not known whether NEP inhibition augments the
0 8
half-life of Lys-des-Arg -bradykinin. Indeed, it has been suggested that the Phe
residue may protect Bi ligands from degradation by NEP [Marceau et al, 1998],
Although the effects of NEP inhibition on systemic haemodynamics are variable
[Northridge et al, 1989; Richards et al, 1990 Bevan et al, 1992; Favrat et al, 1995],
clinical improvements have been reported during NEP inhibition in patients with
heart failure [Northridge et al, 1999].
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Co-administration of ACE and NEP inhibitors may confer additional therapeutic
efficacy. Combined ACE and NEP inhibition attenuates bradykinin degradation more
effectively than either enzyme alone [Dumoulin et al, 2001] and in animal models,
improves cardiac remodelling and survival to a greater extent than isolated ACE
inhibition [Trippodo et al, 1999], These cardioprotective effects are lost in transgenic
mice lacking the B2 kinin receptor [Xu et al, 2004], In man, combined ACE and NEP
inhibition reduces blood pressure to a greater extent than inhibition of either enzyme
alone [Favrat et al, 1995; Campese et al, 2001] and is associated with symptomatic
and haemodynamic improvements in patients with heart failure [McClean et al,
2000], The hypothesis that combined ACE and NEP inhibition may improve
symptoms and survival in patients with heart failure to a greater extent than ACE
inhibition alone has recently been evaluated in a large-scale clinical trial
(OVERTURE) [Packer et al, 2002],
We have previously demonstrated that chronic ACE inhibition potentiates
bradykinin-mediated vasodilatation and endothelial release of t-PA in the forearm
circulation of patients with heart failure [Witherow et al, 2002]. The aims of this
study were to investigate whether local NEP inhibition augments the vascular actions
of bradykinin, and to examine the effects of Bi receptor agonism, in patients with




Ten patients with symptomatic heart failure and echocardiographic evidence of left
ventricular systolic dysfunction attended fasted at 9 a.m. on two occasions at least
2 weeks apart. The protocol was performed with the approval of the Local Research
Ethics Committee, in accordance with the Declaration of Helsinki and with the
written informed consent of each patient. Patients were maintained on maximally
tolerated ACE inhibitor therapy (ramipril - 10 mg daily (n=4), 5 mg daily (n=3);
enalapril - 20 mg daily (n=l), lOmg daily (n=l); lisinopril - 40 mg daily (n=l)) for at
least 6 months prior to recruitment. On the morning of each visit, ACE inhibitor
therapy was administered at 8 a.m. and diuretics were withheld.
5.3.2 Drugs
Pharmaceutical grade thiorphan (Clinalfa AG, Laufelfingen, Switzerland),
bradykinin (Clinalfa AG), Lys-des-Arg9-bradykinin (Clinalfa AG), atrial natriuretic
peptide (Clinalfa AG) and sodium nitroprusside (David Bull Laboratories, Warwick,
United Kingdom) were dissolved in 0.9% saline on the day of study.
5.3.3 Study Design
Following 15 minutes equilibration with 0.9% saline, patients were randomised to
receive an intrabrachial infusion of thiorphan (30 nmol/min) or saline placebo for
3 hours. Thiorphan or placebo was co-infused with bradykinin (30, 100 and 300
pmol/min) [Witherow et al, 2001], Lys-des-Arg9-bradykinin (1, 3 and 10 nmol/min),
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atrial natriuretic peptide (10, 30 and 100 pmol/min; Clinalfa AG) [van der Zander et
al, 1999] and sodium nitroprusside (2, 4 and 8 pg/min) [Newby et al, 1997a] for
10 minutes at each dose. There was a 20 minute washout infusion of 0.9% saline
between compounds. The order of infusion was randomised between patients but was
maintained for both visits. The dose of thiorphan was chosen based on previous
forearm studies [Ferro et al, 1998] to achieve a local plasma concentration > 10-fold
the IC50 of thiorphan for NEP in vitro [Barclay et al, 1990]. The doses of Lys-des-
Arg9-bradykinin were chosen based on binding affinity data [Gobeil et al, 1996] and
the hypotensive dose response in rodents and non-human primates [Drapeau et al,
1991; Deblois et al, 2001], The combined rate of infusion remained constant
throughout each study at 1 mL/min.
5.3.4 Measurements
Bilateral forearm blood flow was measured using venous occlusion plethysmography
[Webb, 1995; Newby et al, 1997b; Wilkinson and Webb, 2001], Heart rate and blood
pressure were recorded in the non-infused arm using a semi-automated non-invasive
oscillometric sphygmomanometer (Takeda UA 751; Takeda) at baseline and in the
final minute of each drug infusion period, after forearm blood flow measurements
and venous sampling. Venous cannulae (17-gauge) were inserted bilaterally into a
large antecubital vein. Throughout each study, 10 mL of blood was collected from
each arm into acidified buffered citrate (Biopool Stabilyte; Umea; for t-PA assays)
and citrate (Monovette, Sarstedt, Numbrecht; for PAI-1 assays). Platelet-free plasma
was prepared as described previously [Newby et al, 1997b] and stored at -70°C
before assay. Plasma concentrations of t-PA and PAI-1 antigen were determined
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using an ELISA, t-PA activity using a photometric method [Newby et al, 1997b], and
ACE activity using colourimetric spectrophotometry (reference range 8 to 55 U/L;
Sigma) [Holmquist et al, 1979].
5.3.5 Data Analysis and Statistics
Data are expressed as mean ± standard error of the mean. Statistical analyses were
performed using ANOVA or, where appropriate, paired /-tests.
5.4 RESULTS
There were no significant differences in heart rate, blood pressure or baseline
forearm blood flow during or between study days (Table 5). Consistent with previous
studies [Brown et al, 2000], one subject developed transient upper limb oedema with
300 pmol/min of bradykinin that rapidly resolved on cessation of the infusion. There
were no other reported side effects.
5.4.1 Plasma ACE Activity
Baseline plasma ACE activity was similar between thiorphan and placebo study
visits (12.3 ± 2.6 versus 9.7 ± 1.5 U/mL respectively; p=0.7). Compared to baseline,
there were no significant differences in plasma ACE activity measured after
90 minutes of thiorphan (10.7 ± 2.5 U/mL; p=0.3) or placebo (10.2 ± 1.7 U/mL;
p=0.3) co-infusion.
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Table 5. Patient characteristics and baseline haemodynamics.
Variable All Patients (n=10) Units
Age (range) 64 (52 - 73) years
Gender (male/female) 5/5 n
Diagnosis (IHD/DCM) 8/2 n
NYHA class (II/III) 6/4 n



















Ejection fraction 31 ±2 %
LVEDD 61 ±3 mm
Baseline heart rate beats/min
Thiorphan visit 58 ±3
Placebo visit 56 ±2
Baseline mean arterial pressure mmHg
Thiorphan visit 92 ±5
Placebo visit 86 ±4
Baseline forearm blood flow mL/lOOmL/min
Thiorphan visit 2.0 ±0.4
Data are expressed as number of patients or mean ± SEM. Mean arterial pressure was calculated as
diastolic pressure plus one-third pulse pressure. IHD, ischaemic heart disease; DCM, idiopathic dilated
cardiomyopathy; NYHA, New York Heart Association; ACE, angiotensin-converting enzyme; LVEDD,
left ventricular end diastolic diameter.
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5.4.2 Forearm Blood Flow
Bradykinin, atrial natriuretic peptide and sodium nitroprusside caused dose-
dependent increases in forearm blood flow in all studies (pO.OOOl for all; Figure
17). Forearm blood flow did not change during Lys-des-Arg9-bradykinin infusion
(Figure 17). Compared to saline placebo, co-infusion of thiorphan augmented
forearm vasodilatation to bradykinin 1.4-fold (p<0.0001; Figure 17) but not atrial
natriuretic peptide or sodium nitroprusside.
5.4.3 Plasma Fibrinolytic Factors
5.4.3.1 Release of t-PA
There were no significant differences in baseline plasma t-PA antigen (10.8 ± 0.9
versus 9.8 ± 0.9 ng/mL), t-PA activity (0.1 ± 0.1 versus 0.4 ± 0.1) or PAI-1 antigen
concentrations (37.3 ± 3.7 versus 38.4 ± 6.2 ng/mL) between thiorphan and placebo
respectively. Bradykinin caused a dose-dependent increase in plasma t-PA antigen
and activity concentrations in the infused arm (p<0.001 for all; Table 6), and the net
release of t-PA antigen and activity in all studies (p<0.005 for all; Figure 18).
Compared to placebo, thiorphan augmented the increase in plasma t-PA activity
concentration (21.9 ± 2.4 versus 24.8 ± 2.6 IU/mL respectively at bradykinin
300 pmol/min; p<0.05; Table 6) in the infused arm and the net release of t-PA
antigen (157 ± 46 versus 233 ± 46 ng/lOOmL/min respectively at bradykinin 300
pmol/min; p<0.005, Figure 18) and activity (155 ± 22 versus 244 ± 51
ng/lOOmL/min respectively at bradykinin 300 pmol/min; p<0.005; Figure 18). There
was a trend towards an increase in t-PA antigen in the infused arm during thiorphan










































Figure 17. Effect of thiorphan (solid circles) and placebo (open circles) on infused forearm blood flow
during intra-arterial infusion of bradykinin, sodium nitroprusside, atrial natriuretic peptide and Lys-des-
Arg9-bradykinin (*p<0.0001, ANOVA dose response; tp<0.0001, ANOVA thiorphan versus placebo).
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ThiorphanInfusio FBF,mL/lOOmL/min Infused Non-infused t-PAantigen,ng/mL Infused Non-infused t-PAactivity,IU/mL Infused Non-infused PlaceboInfusion FBF,mL/IOOmL/min Infused Non-infused t-PAantigen,ng/mL Infused Non-infused t-PAactivity,lU/mL Infused Non-infused
2.1±0.2 1.5±0.3 9.3±0.8 9.6±0.7 0.1±0.1 0.1±0.1 2±0.3 1.9±0.3 9.1±0.7 9.3±0.8 0.3±0.1 0.3±0.1
8.2±0.7 2±0.4 18.0±1.8 10.8±1 8.7±1.4 1.0±0.2 5.8±0.8 2.1±0.4
13±1.5 1,9±0.3 26.2±2.9 12.9±1
19±2.2*J 1.7±0.3 36.5±4.2* 17.6±2.5*
2±0.3 1.4±0.2 10.8±0.9 9.9±0.8
16.2±2.424 8 6*§.3±0.5 3.1±16±1.2t§0.6±0.2 8.3±0.914.4±2.2*J2 2 4 2±0.3.1±0.4
2.4±0.4 1.5±0.3 10.7±0.8 10.4±0.9 1.1±0.4 0.7±0.3 2.6±0.4 2±0.3
3±0.4 l.6±0.3 0.8±0.4 0.5±0.3 3±0.5 2±0.3
3.8±0.6* 1.7±0.3
10.2±0.79.5± 8 10.3±0.99.8±0.8
0.5±0.2 0.4±0.3 3.6±0.6* 2±0.3
14.2±122.8±2.232.5±3.4*9 8±0 84 725 9.8±0.711.2±0.84.6±1.2*0 6.6 4.6±1.312.6±2 421 9 . *§0 0.25 1.43 0.8±0.31 4 42 7t§2 13. 0.I1
2.2±0.3 1.6±0.3 10.1±0.9 10.2±0.9 0.8±0.4 0.7±0.3 2.5±0.3 1.8±0.2 9.6±0.8 9.4±0.8 0.8±0.2 0.3±0.1
2.1±0.3 1.5±0.3 10.2±0.9 10.2±0.9 0.8±0.5 0.2±0.2 2.6±0.3 1.9±0.3 9.7±0.8 9.3±0.8 0.6±0.2 0.3±0.1
2.2±0.3 I.5±0.3 10.1±0.8 10±0.8 0.5±0.3 0.4±0.3 2.7±0.4 1.9±0.3 9.5±0.8 9.2±0.7 0.6±0.2 0.3±0.1
2.1±0.3 1.6±0.3 9.8±0.8 9.6±0.8 0.4±0.2 0.3±0.2 2.7±0.4 1.9±0.3 9.4±0.8 9±9.7 0.6±0.2 0.3±0.2
*p<0.001,f 5ANOVAdosere ponse;J O.OOl,§thiorphavsplacebo.
Figure 18. Effect of thiorphan (solid circles) and placebo (open circles) on net tissue plasminogen
activator (t-PA) antigen (top) and activity (bottom) release during intra-arterial infusion of bradykinin,
and atrial natriuretic peptide (*p<0.005, ANOVA dose response; fp<0.005, ANOVA thiorphan versus
placebo).
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bradykinin 300 pmol/min; p=0.058; Table 6). Due to systemic overspill, bradykinin
increased plasma t-PA antigen and activity concentrations in the non-infused arm
(p<0.01 and p<0.05 respectively; Table 6) that, for t-PA activity, was greater during
thiorphan infusion (p<0.05; Table 6). There were no significant changes in t-PA
antigen, activity or net t-PA release during infusion of atrial natriuretic peptide or
Lys-des-Arg9-bradykinin.
5.4.3.2 Plasma PAI-1 Antigen
Consistent with the augmentation of t-PA release and subsequent PAI-1 mediated
clearance, there was a significant reduction in plasma PAI-1 antigen concentrations
in the infused arm during bradykinin co-infusion with thiorphan (baseline 33.3 ± 3.5
versus 29.4 ±3.4 ng/mL at bradykinin 300 pmol/min; p<0.05) but not placebo
(Table 7). There were no significant changes in PAI-1 antigen concentration during
infusion of Lys-des-Arg9-bradykinin or atrial natriuretic peptide (Table 7).
5.5 DISCUSSION
We have, for the first time, demonstrated that acute local NEP inhibition augments
bradykinin-mediated endothelium-dependent vasodilatation and endogenous t-PA
release in patients with heart failure maintained on chronic ACE inhibitor therapy. In
addition, this is the first clinical study to show that the Bi receptor does not mediate
vasodilatation or endothelial t-PA release in these patients. Our findings support the
hypothesis that bradykinin may contribute to the systemic haemodynamic differences
observed between combined ACE and NEP inhibition, and ACE inhibition alone.
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5.5.1 Clinical Implications
There is now substantial evidence that bradykinin contributes to the systemic
haemodynamic and anti-ischaemic effects of ACE inhibitor therapy [Gainer et al,
1998; Witherow et al, 2001; Witherow et al, 2002; Pretorius et al, 2003], Our
findings suggest that bradykinin-mediated vasodilatation may contribute to the
greater vasodepressor actions demonstrated with combined ACE and NEP inhibition
compared to isolated ACE inhibition [Favrat et al, 1995; Campese et al, 2001].
Moreover, despite the marked increase in bradykinin-induced t-PA release by ACE
inhibition alone [Witherow et al, 2002], additional NEP inhibition causes further
substantial augmentation of acute t-PA release. Taken together, these haemodynamic
and pro-fibrinolytic effects would be expected to have important therapeutic
consequences. However, in the recent OVERTURE trial [Packer et al, 2002] of
patients with heart failure, treatment with omapatrilat, a combined ACE and NEP
inhibitor, failed to reduce all-cause mortality when compared to enalapril, although it
did reduce the combined secondary endpoint of cardiovascular death and
hospitalisation. Post-hoc analysis redefining endpoints according to the Studies of
Left Ventricular Dysfunction (SOLVD) criteria suggested that omapatrilat may be
more effective at preventing cardiovascular events than enalapril, but that the
additional benefit was substantially smaller than anticipated [Packer et al, 2002].
This may, in part, reflect the shorter duration of NEP inhibition compared to ACE
inhibition with omapatrilat [Azizi et al, 2002], Given our findings, pharmacological
strategies offering a more balanced and prolonged duration of combined ACE and
NEP inhibition may confer greater cardiovascular benefits.
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Augmentation of bradykinin-mediated vasodilatation within the kidney may also
contribute to the greater increase in renal blood flow observed with combined ACE
and NEP inhibition than ACE inhibition alone [Regamey et al, 2002]. As a result, it
has been suggested that combined ACE and NEP inhibition may afford greater renal
protection than ACE inhibition alone [Regamey et al, 2002], It should be noted,
however, that potentiating the vascular actions of kinins may have detrimental
effects. Bradykinin has been implicated in the pathogenesis of ACE inhibitor-
mediated angio-oedema [Nussberger et al, 1998], An even greater incidence of
angio-oedema has been reported following treatment with combined ACE and NEP
inhibition [Armstrong et al, 2002]. Our findings are consistent with the suggestion
that bradykinin may contribute to this rare, but potentially life-threatening side effect.
5.5.2 Role of the Bi Receptor
We have demonstrated that intra-arterial Lys-des-Arg9-bradykinin, a potent and
highly selective agonist at the human Bi kinin receptor, has no effect on blood flow
or endothelial t-PA release in the forearm circulation of patients with heart failure
maintained on long-term ACE inhibitor therapy. This is in contrast to our previous
findings that combined Bi and B2 receptor blockade but not isolated selective
blockade of the B2 receptor causes vasoconstriction in patients with heart failure
treated with ACE inhibition [Witherow et al, 2001], We infused Lys-des-Arg9-
bradykinin at a dose that would achieve a local plasma concentration twenty times
greater than those previously shown to produce 50% of the maximal vasomotor
response in both human [Gobeil et al, 1996] and animal studies [Drapeau et al, 1991;
Deblois et al, 2001] and, therefore, our findings are unlikely to reflect an inadequate
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dose. Additional clinical studies using a selective Bj kinin receptor antagonist are
required to more fully investigate the role of the vascular B] receptor in man.
5.5.3 AtrialNatriuretic Peptide andNeutral Endopeptidase
Consistent with previous work demonstrating an impaired forearm vasodilator
response to atrial natriuretic peptide in patients with heart failure [Cockcroft et al,
1989; Hirooka et al, 1990; van der Zander et al, 1999], atrial natriuretic peptide
caused a modest dose-dependent increase in forearm blood flow that was not
augmented by local NEP inhibition. Although suppression of PAI-1 expression in
endothelial cells has been reported in vitro [Pawlowska et al, 2002], we report for the
first time that intra-arterial atrial natriuretic peptide does not directly alter either
plasma PAI-1 or t-PA antigen concentrations in vivo in man.
Local NEP inhibition did not potentiate atrial natriuretic peptide-mediated forearm
vasodilatation in keeping with previous data demonstrating that intrabrachial
thiorphan (30 nmol/min) does not increase endogenous plasma atrial natriuretic
peptide concentrations in the human forearm circulation [Ferro et al, 1998], This
may, at first, appear surprising, given that systemic NEP inhibition augments plasma
atrial natriuretic peptide concentrations in patients with heart failure [Northridge et
al, 1999], Elowever, it is likely to reflect differences in the rate of clearance of atrial
natriuretic peptide and bradykinin from the forearm circulation. The half-life of atrial
natriuretic peptide (~5 minutes) is greater than that of bradykinin (-15 seconds).
Assuming a transit time of the forearm vascular bed of -30 seconds, NEP inhibition
with intrabrachial thiorphan is unlikely to result in sufficient local accumulation of
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atrial natriuretic peptide to augment forearm vasomotor responses. Moreover, the
natriuretic peptide C receptor contributes equally to the clearance of plasma atrial
natriuretic peptide and this pathway is unaffected by NEP inhibition.
5.5.4 Study Limitation
Although selective for NEP, thiorphan may cause some inhibition of ACE activity
and theoretically our findings could represent further inhibition of ACE activity.
Thiorphan exists as two enantiomers that, whilst equipotent for NEP inhibition, have
differing potencies against ACE: selectivity of NEP compared to ACE inhibition of
~50-fold for (S)-thiorphan and 200-fold for (R)-thiorphan [Roques et al, 1993], The
preparation of thiorphan used in this study contains equal proportions of both
isomers [Roques et al, 1993]. We do not believe that the effects of thiorphan were
mediated through additional inhibition of ACE activity because local thiorphan
infusion did not alter plasma ACE activity. Moreover, in a previous study [Ferro et
al, 1998] using the same dose of thiorphan, there were no effects on plasma
angiotensin II concentrations in the forearm circulation of healthy volunteers treated
acutely with enalapril. However, we acknowledge that ACE inhibition by maximally
tolerated doses of an ACE inhibitor may be incomplete [Jorde et al, 2000], and we
cannot completely exclude a contribution of additional ACE inhibition to our study
findings.
In conclusion, we have demonstrated that local NEP inhibition augments bradykinin-
mediated vasodilatation and endothelial t-PA release in patients with heart failure
maintained on long-term ACE inhibitor therapy. Using a potent Bj receptor agonist,
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we have shown that isolated stimulation of the Bi kinin receptor does not cause
vasodilatation or endothelial t-PA release in man. These findings confirm that NEP
contributes to the metabolism of bradykinin in patients with heart failure and suggest
that potentiation of the vascular and pro-fibrinolytic actions of bradykinin may




THE Bi KININ RECEPTOR DOES NOT CONTRIBUTE TO VASCULAR
TONE OR TISSUE PLASMINOGEN ACTIVATOR RELEASE IN PATIENTS




Vascular B] kinin receptor expression is markedly upregulated with left ventricular
dysfunction and ACE inhibition but its function in man remains unknown. We
investigated the contribution of the Bi receptor to the maintenance of vascular tone
and t-PA release in patients with heart failure. Eleven patients with heart failure were
withdrawn from ACE inhibitor therapy for 2 weeks before receiving 6 weeks of
enalapril (10 mg bd) or losartan (50 mg bd) in a randomised double-blind cross-over
study. Patients received an intrabrachial infusion of Lys-des-Arg9-bradykinin (Bi
agonist; 1-10 nmol/min), bradykinin (B2 agonist; 30-300 pmol/min), sodium
O Q
nitroprusside (2-8 pg/min), Lys-[Leu ]-des-Arg -bradykinin (Bi antagonist;
1-10 nmol/min), HOE-140 (1.5-13nmol/min) and norepinephrine (60-540 pmol/min).
Blood flow and t-PA release were measured using venous occlusion
plethysmography and blood sampling. Bradykinin and sodium nitroprusside caused
dose-dependent vasodilatation (p<0.0001 for all). Norepinephrine caused
vasoconstriction (p<0.0005 for all). Lys-des-Arg9-bradykinin, Lys-[Leu8]-des-Arg9-
bradykinin and EIOE-140 had no effect on blood flow. Bradykinin (p<0.001 for all),
but not Lys-des-Arg9-bradykinin, caused dose-dependent t-PA antigen and activity
release. Compared to ACE inhibitor withdrawal or losartan, enalapril augmented
bradykinin-mediated vasodilatation (p<0.05 for both) and t-PA release (p<0.01 for
all) but had no effect on responses to sodium nitroprusside, Lys-des-Arg9-bradykinin,
Lys-[Leu8]-des-Arg9-bradykinin, HOE-140 or noradrenaline. The Bj kinin receptor
does not have a major vasomotor or fibrinolytic role in patients with heart failure.
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Augmentation of kinin-mediated vasodilatation and t-PA release by ACE inhibitor
therapy is restricted to the B2 receptor.
6.2 INTRODUCTION
Bradykinin is the major effector for the kinin family of peptides in man. It is released
at sites of inflammation and coagulation and contributes to the systemic
haemodynamic (Chapter 4) [Gainer et al, 1998] and anti-ischaemic [Witherow et al,
2002; Pretorius et al, 2003] effects of ACE inhibitor therapy. Besides vasodilatation,
bradykinin stimulates endothelial release of the pro-lytic factor, t-PA, and these
effects are mediated by the constitutively expressed B2 kinin receptor [Brown et al,
2000],
Des-Arg9-bradykinin is the principal ligand for the B\ kinin receptor in human
plasma and is generated by carboxypeptidases following removal of the C-terminal
arginine from bradykinin. The vascular Bi receptor is normally expressed very
weakly but is markedly upregulated in the presence of inflammation [Deblois and
Horlick, 2001], ischaemic left ventricular dysfunction [Tschope et al, 2000],
cardiovascular disease [McLean et al, 2000b] and ACE inhibition [Whalley et al,
1989; Marin-Castano et al, 2002], In animal studies, stimulation of the Bi receptor
produces vasodilatation and a reduction in blood pressure [Drapeau et al, 1991;
Nakhostine et al, 1993; Su et al, 2000; Deblois and Horlick, 2001]. Intense
endothelial Bi receptor expression has been demonstrated in atheromatous human
blood vessels [Raidoo et al, 1997] and B] receptor stimulation induces dose-
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dependent vasodilatation in human coronary arteries in vitro [Drummond and Cocks,
1995b], Whether the Bi receptor contributes to the vascular effects of kinins in vivo
in man remains unknown.
Angiotensin-converting enzyme is the principal enzyme responsible for the rapid
breakdown of bradykinin (plasma half-life ~15 seconds) to its inactive metabolites
[Marceau et al, 1998], In addition to increasing plasma bradykinin concentrations,
ACE inhibition will favour bradykinin breakdown by alternative metabolic pathways
including plasma carboxypeptidases, augmenting the generation of des-Arg9-
bradykinin and thereby potentiating both Bi and B2 receptor mediated effects
[Marceau et al, 1998]. B2 receptor antagonism attenuates the vasodepressor effect of
a single oral dose of captopril in healthy volunteers and subjects with hypertension
[Gainer et al, 1998]. In patients with heart failure, the combined Bi and B2 kinin
receptor antagonist, B9340, causes vasoconstriction in the forearm circulation in the
presence, but not absence of ACE inhibition [Witherow et al, 2001], and when
administered systemically, attenuates the haemodynamic effects of chronic ACE
inhibition (Chapter 4). However, the role of the vascular Bi kinin receptor in patients
with heart failure and those treated with ACE inhibitor therapy remains to be
established.
Although des-Arg9-bradykinin is the principal Bi agonist present in plasma, it has
only modest affinity for the human Bi receptor and retains some activity at the
human B2 receptor [Marceau et al, 1998], Indeed, des-Arg9-bradykinin is only 100-
fold more selective for the human Bi receptor [Marceau et al, 1998], In contrast, Lys-
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des-Arg9-bradykinin, an endogenous tissue-based metabolite of kallidin, has
~1000-fold greater affinity for the Bi receptor than des-Arg9-bradykinin, and is
inactive at the B2 receptor in man [Gobeil et al, 1996; Marceau et al, 1998;
Christiansen et al, 2002], Substitution of the Phe8 residue in Lys-des-Arg9-bradykinin
O Q
with leucine results in the formation of Lys-[Leu ]-des-Arg -bradykinin, a synthetic
peptide with potent selective inhibitory activity at the human Bi receptor [Marceau et
al, 1998; Deblois and Horlick, 2001].
The aims of this study were to investigate whether the Bj receptor contributes to the
vascular actions of kinins in the patients with heart failure treated with ACE inhibitor
therapy. Using intrabrachial infusion of custom manufactured, clinical grade
peptides, we examined the effects of selective kinin receptor agonism and
antagonism on vascular tone and endothelial t-PA release in patients with heart
failure maintained on long-term ACE inhibition.
6.3 METHODS
6.3.1 Patients
Eleven patients with symptomatic heart failure (NYHA class II or III) and evidence
of left ventricular systolic dysfunction (ejection fraction <40%, shortening fraction
<20% or left ventricular end-diastolic dimension >55 mm) were recruited. Patients




Pharmaceutical grade bradykinin (Clinalfa AG, Laufelfingen, Switzerland), Lys-des-
Arg9-bradykinin (Clinalfa), Lys-[Leu8]-des-Arg9-bradykinin (Clinalfa), HOE-140
(Clinalfa), sodium nitroprusside (Mayne Pharma pic, Warwickshire, UK) and
norepinephrine (Abbott Laboratories Ltd, Maidenhead, UK) were dissolved in
physiological saline on the day of study. The doses of bradykinin, HOE-140, sodium
nitroprusside and norepinephrine were chosen based on the results of previous
Q O
studies [Newby et al, 1997a], The doses of Lys-des-Arg -bradykinin and Lys-[Leu ]-
des-Arg9-bradykinin were chosen based on the EC50 (Bi receptor, 0.2 nmol/L; EL
receptor, >30000 nmol/L) and IC5o(Bi, 1-3 nmol/L; B2, >30000 nmol/L) respectively
for human kinin receptors in vitro [Marceau et al, 1998], data from human umbilical
vein myography studies [Gobeil et al, 1996; Sardi et al, 1998] and the hypotensive
dose response in rodents and non-human primates [Drapeau et al, 1991; Deblois and
Horlick, 2001],
6.3.3 Study Design
Where symptoms would allow, ACE inhibitor therapy was withdrawn for a period of
2 weeks (n=7). Following this and in place of their usual ACE inhibitor, patients
were randomised to receive 6 weeks of treatment with enalapril 10 mg
[CONSENSUS, 1987] twice daily or losartan 50 mg [Pitt et al, 2000] twice daily in a
double-blind, cross-over trial. One patient withdrew due to worsening symptoms and
was replaced. During week 2 of ACE inhibitor withdrawal and weeks 6 and 12 of the
cross-over trial, patients attended on two occasions at least 3 days apart and
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underwent an agonist infusion protocol on one occasion and an antagonist infusion
protocol on the other. The study order remained constant for each patient but was
randomised between patients.
6.3.4 Drug Infusion Protocol
Study drugs were infused in random order for 10 minutes at each dose and separated
by a 20 minute infusion of 0.9% saline.
6.3.4.1 Agonist Protocol
After 30 minutes equilibration with 0.9% saline, patients received an intrabrachial
infusion of Lys-des-Arg9-bradykinin (1, 3 and 10 nmol/min), bradykinin (30, 100
and 300 pmol/min) and sodium nitroprusside (2, 4 and 8 pg/min).
6.3.4.2 Antagonist Protocol
After 30 minutes equilibration with 0.9% saline, patients received an intrabrachial
infusion of Lys-[Leu8]-des-Arg9-bradykinin (1, 3 and 10 nmol/min), HOE-140 (1.5,
4 and 13 nmol/min) and norepinephrine (60, 180 and 540 pmol/min).
6.3.5 Data Analysis
Data were examined by two-way ANOVA with repeated measures and two-tailed
Student's t-test using GraphPad PRISM (GraphPad). All results are expressed as
mean ± standard error of the mean. Statistical significance was taken at the 5% level.
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6.4 RESULTS
Patients were predominantly male with mild to moderate congestive heart failure due
to ischaemic heart disease (Table 8). There were no significant differences in heart
rate, blood pressure or baseline forearm blood flow during or between study days
(Table 9).
6.4.1 Plasma Neurohormone Concentrations
Compared to losartan, plasma ACE activity (42.2 ± 11 versus 10.5 ± 6.1 Units/L
respectively; p<0.05) and angiotensin II concentrations (24.4 ± 6.3 versus 7.8 ± 1.6
pg/mL respectively; p<0.05) were lower during treatment with enalapril (Figure 19).
6.4.2 Forearm Blood Flow
6.4.2.1 Agonist Protocol
Bradykinin (p<0.0001 for all) and sodium nitroprusside (p<0.0001 for all), but not
Lys-des-Arg9-bradykinin (p=not significant for all), caused dose-dependent
vasodilatation in all studies (Figure 20). Bradykinin-mediated vasodilatation was
augmented in patients treated with enalapril compared to losartan (p<0.005; Figure
20) or ACE inhibitor withdrawal (p<0.05; Figure 20).
6.4.2.2 Antagonist Protocol
o q
Norepinephrine (p<0.0005 for all), but not Lys-[Leu ]-des-Arg -bradykinin or HOE-
140 (p=not significant for all), caused dose-dependent vasoconstriction in all studies
(Figure 21).
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Table 8. Patient characteristics.
Variable All Patients (n=10) Units
Age 68 (53 - 79) years (range)
Gender 10/1 male/female
Diagnosis 9/2 IHD/DCM
NYHA class 7/4 II/III
















Ejection fraction 36 ±3 %
LVEDD 63 ±2 mm
Data are expressed as number of patients or mean ± SEM unless indicated. IHD, ischaemic heart disease;
DCM, idiopathic dilated cardiomyopathy; NYHA, New York Heart Association; ACE, angiotensin-
converting enzyme; LVEDD, left ventricular end diastolic diameter.
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Table 9. Baseline haemodynamics.





































Data are expressed as mean ± SEM. Mean arterial pressure was calculated as diastolic pressure plus one-
third pulse pressure.
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6.4.3 Fibrinolytic Factors
6.4.3.1 Release of t-PA
Bradykinin (p<0.001 for all), but not Lys-des-Arg9-bradykinin (p=not significant for
all), caused dose-dependent increases in plasma concentrations of t-PA antigen and
activity in the infused arm and net release of t-PA antigen and activity in all studies
(Figure 22). The bradykinin-mediated increase in plasma t-PA antigen and activity in
the infused arm, and net release of t-PA antigen and activity was augmented in
patients treated with enalapril compared to losartan (p<0.0005 for all) or ACE
inhibitor withdrawal (p<0.005 for all; Figure 22).
Consistent with systemic overspill [Witherow et al, 2002], bradykinin caused dose-
dependent increases in plasma t-PA antigen and activity concentrations in the non-
infused arm with enalapril therapy, and plasma t-PA antigen alone following ACE
inhibitor withdrawal (p<0.0001 for all; Figure 22). Enalapril augmented the increase
in t-PA compared to losartan therapy or ACE inhibitor withdrawal (p<0.01 for both;
Figures 22 and 23).
6.4.3.2 Plasma PAI-1 Antigen
There were no significant differences in basal PAI-1 antigen concentrations between
study days. Consistent with an increase in PAI-1 mediated clearance following
marked t-PA release [Chandler et al, 1997], and a potential time effect [Brown et al,
2002], plasma PAI-1 antigen concentrations fell during infusion of bradykinin in
both the infused (47.6 ± 7.9 ng/mL at baseline versus 43.8 ± 7 ng/mL during
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versus 44.5 ± 7 ng/mL during bradykinin 300 pmol/min; p<0.05) in patients treated
with enalapril but not losartan or during ACE inhibitor withdrawal.
6.5 DISCUSSION
This is the first study to characterise the potential vasomotor and fibrinolytic role of
the vascular Bi kinin receptor in vivo. We have demonstrated that the peptidic B]
receptor agonist, Lys-des-Arg9-bradykinin, and antagonist, Lys-[Leu8]-des-Arg9-
bradykinin have no effect on vascular tone or endothelial t-PA release in the presence
or absence of ACE inhibition. In contrast, and consistent with our previous unblinded
and non-randomised data [Witherow et al, 2002], ACE inhibition markedly
augmented the vascular actions of bradykinin mediated via the B2 receptor. We
conclude that the Bi receptor does not appear to have a major vasomotor or
fibrinolytic role in the forearm circulation of patients with heart failure treated with
chronic ACE inhibition.
Our findings are in contrast to previous in vitro and animal work demonstrating
vasodilatation following Bi receptor stimulation [Drapeau et al, 1991; Nakhostine et
al, 1993; Su et al, 2000; Deblois and Horlick, 2001; Marin-Castano et al, 2002].
Before concluding that the Bi kinin receptor does not mediate vasodilatation or
endothelial t-PA release in the forearm circulation of patients with heart failure, we
must first consider the following possibilities: the doses of the Lys-des-Arg9-
o q
bradykinin and Lys-[Leu ]-des-Arg -bradykinin used in this study were inadequate;
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the custom-made peptides lacked biological activity; or the extent of ACE inhibition
was insufficient to upregulate Bi receptor expression.
We infused Lys-des-Arg9-bradykinin at a dose which was at least 20-fold greater than
that previously shown to produce 50% of the maximal hypotensive response in both
primate (EC50 ~ 0.1 pmol/kg)6 and rodent studies (ECso~ 0.3 pmol/kg) [Drapeau et al,
O Q
1991]. Similarly, Lys-[Leu ]-des-Arg-bradykinin was infused at a dose 20-fold
greater than that previously shown to abolish Bi receptor mediated vasomotor
responses in animal models in vivo [Drapeau et al, 1991; Deblois and Horlick, 2001],
To address the issue of biological activity, we have examined vasomotor responses to
the custom manufactured B] agonist and antagonist in isolated human umbilical vein
(Chapter 3) [Sardi et al, 1998]. The concentration-response curves obtained for Lys-
des-Arg9-bradykinin and Lys-[Leu8]-des-Arg9-bradykinin were comparable with data
from previous studies (Chapter 3) [Gobeil et al, 1996; Sardi et al, 1998] and confirm
efficacy at concentrations predicted to be achieved in the infused human forearm
circulation.
Previous rodent studies have demonstrated that, besides cardiovascular inflammation,
chronic ACE inhibition upregulates functional vascular Bi receptor expression
[Marin-Castano et al, 2002], We have examined Bi receptor function in patients with
heart failure treated with an effective evidence based dose of enalapril
[CONSENSUS, 1987], Moreover, plasma concentrations of angiotensin II and ACE
activity confirmed significant inhibition of the renin-angiotensin system with
enalapril at this dose. From our findings, therefore, we can conclude that the Bi kinin
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receptor does not mediate vasodilatation or endothelial t-PA release in patients with
mild to moderate heart failure treated with long-term ACE inhibitor therapy.
We have previously demonstrated that combined Bi and B2 receptor blockade, but not
B2 receptor blockade, causes peripheral vasoconstriction in patients with heart failure
treated with ACE inhibition. In our current study, however, selective Bi receptor
antagonism had no effect on peripheral vascular tone. One potential explanation for
this discrepancy is that the Bi receptor may only mediate the vasomotor effects of
kinins in the absence of B2 receptor mediated signalling. In support of this hypothesis,
the Bi and B2 kinin receptors are coupled to similar G-protein subtypes and share the
same intracellular signalling pathways [Leeb et al, 1997; Marceau et al, 1998], In
transgenic mice lacking the B2 kinin receptor, the Bi receptor is upregulated and
assumes vascular functions normally associated with the B2 receptor [Duka et al,
2001]. Consistent with these data, we have demonstrated that the B2 receptor
antagonist, HOE-140, augments the vasomotor responses to the Bi agonist, Lys-des-
Arg9-bradykinin, in human umbilical vein in vitro (Chapter 3). Future studies
examining the effects of Bi receptor agonism and antagonism during concomitant
administration of HOE-140 may help clarify the issue of kinin receptor cross-talk in
the peripheral circulation of patients with heart failure.
6.5.1 Study Limitations
It has been suggested that the extent of the inflammatory response in patients with
congestive cardiac failure correlates with the severity of underlying heart failure
[Levine et al, 1990]. We have examined Bi receptor function in patients with mild to
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moderate (NYHA class II-III) heart failure. We cannot exclude the possibility that
vascular Bj receptor expression may be restricted to patients with severe end-stage
heart failure. In addition, the B) kinin receptor has been implicated in a number of
alternative biological processes, including leukocyte trafficking [McLean et al,
2000a] and ischaemia-induced angiogenesis [Emanueli et al, 2002]. It remains
possible that Bj receptors, mediating processes other than vasodilatation or
endogenous fibrinolysis, may be present in the human forearm vasculature. Finally,
we have examined Bi mediated responses in the forearm circulation of patients with
heart failure. Specific vascular beds may differ in their response to Bj agonists and
the current findings cannot be extrapolated to the entire vasculature.
In conclusion, contrary to data from animal studies, we have demonstrated for the
first time that the B] kinin receptor does not mediate vasodilatation or endothelial
t-PA release in the peripheral circulation of patients with heart failure treated with
long-term ACE inhibition. Our findings suggest that the beneficial vascular effects of
ACE inhibitor therapy attributed to kinins are restricted to those mediated by the B2
receptor and do not support a major role for the Bj kinin receptor as a potential
therapeutic target in patients with heart failure.
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CHAPTER 7
CONCLUSIONS AND FUTURE DIRECTIONS
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7.1 INTRODUCTION
Chronic heart failure is a common condition in western society that is associated with
significant mortality and morbidity. Activation of the renin-angiotensin-aldosterone
system plays a key role in the salt and water retention and vasoconstriction central to
the pathogenesis of this condition. Recently, it has become clear that the plasma
kinin system acts as a counterbalance for the renin-angiotensin-aldosterone system
[Schmaier, 2002], Intimately involved with both these biological systems is the
membrane-bound metallopeptidase, ACE, responsible both for the breakdown of
bradykinin and the production of angiotensin II. It is now widely accepted that
inhibitors of ACE improve symptoms and survival in patients with chronic heart
failure and there is increasing evidence that these effects may be mediated, at least in
part by potentiation of bradykinin. Confirmation of this hypothesis in patients with
heart failure should support the development of novel therapeutic strategies to further
augment the vascular actions of bradykinin in the belief that this may afford greater
cardiovascular benefit.
The vascular effects of plasma kinins are mediated by two principal receptor
subtypes, Bi and B2. Until recently, attention has focused on the constitutively
expressed endothelial B2 receptor and the role of the inducible human vascular Bi
receptor in vivo remains unclear. A number of metabolic pathways exist in plasma
that result in the production or degradation of kinins selective for a specific receptor
subtype. Therefore, inhibitors of specific plasma enzymes responsible for kinin
metabolism may shift the equilibrium within the plasma kinin system in favour of
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either the B] or B2 kinin receptor. Hence, determining the relative contribution of the
Bi kinin receptor to the vasomotor and fibrinolytic effects of plasma kinins in
patients with heart failure is crucial both for our understanding of the mechanism of
action of ACE inhibitor therapy and for the development of novel therapies targeting
specific kinin receptor mediated effects such as vasodilatation and endothelial t-PA
release.
Using local and systemic infusions of bradykinin and related peptides combined with
robust physiological models for assessing vascular function in vivo, we have
addressed these important questions through a series of randomised, double-blind,
controlled trials in patients with heart failure.
7.2 BIOLOGICAL EFFICACY OF KININ-RELATED PEPTIDES
Prior to use in clinical studies, the biological efficacy of the custom-made peptides,
Lys-des-Arg9-bradykinin, bradykinin, Lys-[Leu8]-des-Arg9-bradykinin and HOE-
140, obtained from Clinalfa was examined in human umbilical vein in vitro. The data
obtained confirm that these custom-made peptides have similar biological efficacy
and potency at the human Bj receptor as established commercially available
laboratory grade peptides [Gobeil et al, 1996; Sardi et al, 1998; Sardi et al, 1999].
Consistent with previous work [Gobeil et al, 1996; Sardi et al, 1998; Sardi et al,
1999], Lys-des-Arg9-bradykinin, a Bi receptor agonist, and bradykinin, a B2 receptor
agonist, caused dose-dependent vasoconstriction that was selectively inhibited by
8 Q
their respective antagonists, Lys-[Leu ]-des-Arg -bradykinin and HOE-140. The
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combined Bi and B2 receptor antagonist, B9340, attenuated vasomotor responses to
both Lys-des-Arg9-bradykinin and bradykinin. In contrast, however, the B2 receptor
antagonist, HOE-140, shifted the dose response curve for Lys-des-Arg9-bradykinin to
the left, suggesting potentiation of Bi receptor mediated responses in the presence of
B2 receptor antagonism. These functional data are supported by
immunohistochemical evidence of Bi and B2 kinin receptor expression on vascular
smooth muscle cells in human umbilical vein rings.
7.3 BRADYKININ CONTRIBUTES TO THE SYSTEMIC
HAEMODYNAMIC EFFECTS OF ACE INHIBITION
Consistent with previous findings in vitro [Stewart et al, 1997] and in vivo
[Witherow et al, 2003], we have demonstrated using human umbilical myography
that B9340 is a selective, reversible peptidic kinin antagonist with similar efficacy at
both the Bi and B2 kinin receptor. When administered intravenously, B9340 caused
systemic inhibition of bradykinin-mediated vasodilatation in a dose-dependent
manner in healthy volunteers. Furthermore, we have demonstrated that B9340 has a
significant pressor effect (~5 mmHg increase in mean arterial pressure) in patients
with chronic heart failure maintained on long-term ACE inhibitor but not angiotensin
receptor blocker therapy. These data provide convincing evidence that bradykinin
contributes to the systemic haemodynamic effects of long-term ACE inhibition in
patients with heart failure.
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Given the proven therapeutic benefits of ACE inhibitor therapy in patients with heart
failure [CONSENSUS, 1987; Flather et al, 2000] and vascular disease [Yusuf et al,
2000; Fox, 2003], these findings provide additional support for bradykinin and, in
particular, inhibitors of bradykinin metabolism as potential therapeutic targets in the
treatment of cardiovascular disease. Indeed, additional inhibitors of bradykinin
metabolism may further potentiate the vascular effects of bradykinin in patients
already maintained on ACE inhibitor therapy. To investigate this hypothesis, we
chose to examine the effect of inhibition of NEP on the vascular actions of
bradykinin in the peripheral circulation of patients with heart failure maintained on
chronic ACE inhibitor therapy.
7.4 EFFECT OF COMBINED ACE AND NEP INHIBITION ON THE
VASCULAR ACTIONS OF BRADYKININ
We have demonstrated for the first time in patients with heart failure treated with
ACE inhibition, that the haemodynamic and pro-fibrinolytic effects of bradykinin are
significantly augmented by additional local NEP inhibition. Our findings suggest that
bradykinin-mediated vasodilatation may contribute to the greater vasodepressor
action observed with combined ACE and NEP inhibition when compared to isolated
ACE inhibition [Favrat et al, 1995; Armstrong et al, 2002], Moreover, given the
undeniable success of ACE inhibitor therapy in the treatment of patients with heart
failure, these findings would be expected to have important therapeutic
consequences.
135
In the recent OVERTURE trial [Packer et al, 2002] of patients with heart failure,
treatment with omapatrilat, a combined ACE and NEP inhibitor, failed to reduce all-
cause mortality when compared to enalapril, although it did reduce the combined
secondary endpoint of cardiovascular death and hospitalisation. Post-hoc analysis
redefining endpoints according to the SOLVD criteria suggested that omapatrilat
may be more effective at preventing cardiovascular events than enalapril, but that the
additional benefit was substantially smaller than anticipated [Packer et al, 2002],
These data are in keeping with the marked augmentation of endothelial t-PA release
with ACE inhibition previously observed in patients with heart failure [Witherow et
al, 2002] compared to the smaller additional benefit associated with combined ACE
and NEP inhibition demonstrated in this study. The apparent lack of benefit in
OVERTURE (Packer et al, 2002) may also, in part, reflect the shorter duration of
NEP inhibition, relative to ACE inhibition, with omapatrilat [Azizi et al, 2002].
Given our findings, pharmacological strategies that offer a more balanced and
prolonged duration of combined ACE and NEP inhibition may confer greater
cardiovascular benefit.
In contrast to bradykinin, local NEP inhibition did not potentiate atrial natriuretic
peptide-mediated forearm vasodilatation. This may, at first, appear surprising, given
that systemic NEP inhibition augments plasma atrial natriuretic peptide
concentrations in patients with heart failure [Northridge et al, 1999]. However, local
NEP inhibition with thiorphan (30 nmol/min) does not increase endogenous plasma
atrial natriuretic peptide concentrations in the human forearm circulation [Ferro et al,
1998], This is likely to reflect differences in the rate of clearance of atrial natriuretic
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peptide and bradykinin from the forearm circulation. The half-life of atrial natriuretic
peptide (~5 minutes) is greater than that of bradykinin (-15 seconds). Assuming a
transit time of the forearm vascular bed of ~30 seconds, acute local NEP inhibition is
unlikely to result in sufficient local accumulation of atrial natriuretic peptide to
augment forearm vasomotor responses. Moreover, besides NEP, the natriuretic
peptide C receptor contributes to a similar extent to the clearance of plasma atrial
natriuretic peptide and this pathway is unaffected by NEP inhibition.
7.5 FUNCTIONAL ROLE OF SPECIFIC KININ RECEPTORS
7.5.1 Bi Kinin Receptor
In contrast to data from animal models of inflammation and cardiovascular disease,
we have demonstrated that the peptidic Bj receptor agonist, Lys-des-Arg9-
O Q
bradykinin, and antagonist, Lys-[Leu ]-des-Arg -bradykinin, have no effect on
vascular tone or endothelial t-PA release. Whilst these data hold true for the forearm
circulation of patients with mild to moderate heart failure, we must first consider a
number of potential limitations before extrapolating our findings to the human
vasculature as a whole.
Historically, the forearm circulation has been considered relatively protected from
atheroma for reasons that remain unclear. The only previous study of human vascular
Bi kinin receptor expression has suggested that Bi kinin receptor expression may be
concentrated in atheromatous plaques [Raidoo et al, 1997]. Therefore, functional B]
kinin receptors may be restricted to vascular beds with high atheroma burden such as
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the coronary or femoral circulations. Moreover, specific vascular beds may differ in
their response to Bi agonists, independent of the burden of atheromatous disease.
We have examined Bi receptor function in patients with mild to moderate (NYHA
class II-III) heart failure. It has been suggested that the inflammation associated with
heart failure correlates with the severity of disease. Assuming a sufficient
inflammatory stimulus is required for Bj receptor expression, we cannot exclude the
possibility that vascular Bi receptor expression may be restricted to patients with
severe end-stage heart failure.
The Bi kinin receptor has been implicated in a number of alternative biological
processes, including leucocyte trafficking [McLean et al, 2000a] and ischaemia-
induced angiogenesis [Emanueli et al, 2002], It remains possible that Bi receptors,
mediating processes other than vasodilatation or endogenous fibrinolysis, may be
present in the human forearm vasculature.
7.5.2 B2 Kinin Receptor
Consistent with previous work [Witherow et al, 2001; Witherow et al, 2002],
bradykinin caused dose-dependent vasodilatation and endothelial t-PA release in the
peripheral circulation of patients with heart failure. Previous work in healthy
volunteers has demonstrated that these effects are mediated through the B2 kinin
receptor by a nitric oxide synthase- and cyclooxygenase-independent pathway
[Brown et al, 2000]. Although endothelium-derived hyperpolarising factor has been
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implicated, the downstream signalling mechanism resulting in t-PA release following
B2 receptor activation remains unclear [Brown et al, 2000].
7.5.3 ACE Inhibition and Kinin Receptor Function
Inhibition of ACE had no effect on Bi receptor mediated vasodilatation or t-PA
release in patients with heart failure. Bearing in mind the potential limitations
discussed above, it can be concluded that the Bi receptor does not have a major
vasomotor or fibrinolytic role in the forearm circulation of patients with heart failure
treated with chronic ACE inhibition.
The effect of ACE inhibition on vascular Bi expression remains controversial. Whilst
some investigators have reported upregulation of functional Bi receptor expression in
the systemic circulation [Nwator and Whalley, 1989; Marin-Castano et al, 2002],
data from the present study and others [Deblois et al, 1991; Marceau et al, 1999] do
not support this hypothesis. This apparent conflict may be due to differences in
species- or vascular bed-specific responses, or may reflect a requirement for
concomitant signalling processes occurring in specific pathological states associated
with increased Bi receptor expression.
In contrast to Bi receptor mediated responses, inhibition of ACE significantly
augmented bradykinin-mediated vasodilatation (~2-fold) and endothelial t-PA
release (~6-fold) in a randomised, double-blind, controlled trial of patients with heart
failure, when compared to losartan therapy or withdrawal of agents blocking the
renin-angiotensin system. These findings confirm the results of our earlier
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non-randomised and unblinded work [Witherow et al, 2002] and provide further
support for a role for bradykinin in the anti-ischaemic effects of ACE inhibitor
therapy.
The major clinical benefits of ACE inhibition have been incontrovertibly established
in patients with coronary artery disease. Although first demonstrated in patients with
heart failure, it is now clear from the HOPE [Yusuf et al, 2000], EUROPA [Fox,
2003] and PEACE [Braunwald et al, 2004] trials that the clinical benefits of ACE
inhibitor therapy extend to patients with cardiovascular disease and normal left
ventricular systolic function. Indeed, when comparing these studies with the meta¬
analyses of heart failure trials [Flather et al, 2000] there is a clear and remarkably
consistent anti-ischaemic effect of ACE inhibitors with a 20-22% relative risk
reduction in the rate ofmyocardial infarction.
In contrast, the beneficial effects on mortality appear to depend upon the overall
cardiovascular risk of the patient: greatest in those with severe left ventricular
dysfunction and least in those at low risk with preserved left ventricular dysfunction.
Thus, both the augmentation of bradykinin-induced vasodilatation and the marked
(6- to 10-fold) increase in t-PA release described with ACE inhibition in patients
with coronary artery disease may contribute to the primary mechanism of the anti-
ischaemic effects associated with chronic ACE inhibitor therapy. Consistent with this
hypothesis, ACE inhibitor therapy reduces myocardial troponin release in patients
with acute coronary syndromes [Kemion et al, 2001], The development of novel
therapies potentiating the vascular actions of bradykinin mediated by the B2 receptor
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has the potential, therefore, to provide clinical benefits both in the treatment of
congestive heart failure and atheromatous vascular disease. These will be discussed
below.
7.6 FUTURE DIRECTIONS
7.6.1 Bi Receptor and Atherosclerosis
There is now a substantial body of evidence that systemic inflammation plays an
important role in the pathogenesis of atherosclerosis [Ross, 1999]. Moreover, human
postmortem studies have indicated that Bj receptors are markedly upregulated in the
presence of atherosclerosis [Raidoo et al, 1997]. Although we have examined the
effects of Bi receptor agonism and antagonism in the forearm circulation of patients
with heart failure predominantly due to ischaemic heart disease, it is widely accepted
that the forearm vascular bed is relatively protected from atherosclerotic plaque
formation. Further work is required to define the effects of Bi kinin receptor agonism
and antagonism on vascular tone and endogenous fibrinolysis in human
atherosclerotic arteries in vivo.
We are currently examining the relationship between atherosclerosis and Bj kinin
receptor mediated vasomotor and fibrinolytic effects as part of an on-going British
Heart Foundation Research Project (PG/02/092). Using intravascular ultrasound
(IVUS), Doppler flow measurements and arteriovenous sampling combined with
selective intra-arterial infusions [Newby, 2000], this study will examine the effect of
selective kinin receptor agonists and antagonists on blood flow and t-PA release in
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the femoral circulation of patients undergoing routine diagnostic coronary
angiography. During the study, motorised pullback of the IVUS catheter permits
accurate quantification of the atheromatous plaque burden for a given length of the
vessel being studied. Given the significant levels of plaque burden in the femoral
circulation in patients with suspected coronary artery disease, this study will allow us
to directly address the question of whether atherosclerosis is associated with
functional B i receptor expression.
7.6.2 Kinin Receptor Interactions
It has previously been demonstrated that combined B] and B2 receptor blockade, but
not B2 receptor blockade alone, causes peripheral vasoconstriction in patients with
heart failure treated with ACE inhibition [Witherow et al, 2001], In the data reported
here, however, selective Bj receptor antagonism had no effect on peripheral vascular
tone. One potential explanation for this discrepancy is that the Bi receptor may only
mediate the vasomotor effects of kinins in the absence of B2 receptor mediated
signalling. In support of this hypothesis, the Bj receptor is upregulated in transgenic
mice lacking the B2 kinin receptor where it assumes the vasomotor functions
normally associated with the B2 receptor [Duka et al, 2001]. These findings are
perhaps not surprising given that the Bi and B2 kinin receptors are coupled to similar
membrane associated G-proteins and share common intracellular signalling pathways
[Marceau et al, 1998; Leeb-Lundberg et al, 2005], The hypothesis that significant
cross-talk exists between the Bi and B2 kinin receptors is supported by the data
presented in Chapter 3 demonstrating that B2 receptor antagonism augments Bi
mediated vasomotor responses in human umbilical vein in vitro.
142
We are currently undertaking further studies to characterise the nature of this
receptor interaction in vivo in the forearm circulation of patients with heart failure.
Using the forearm model employed in Chapters 5 and 6, the effects of Bi receptor
antagonism on vasomotor tone and t-PA release will be examined during co-infusion
of the B2 antagonist in a randomised double-blind placebo controlled trial. A similar
study will be performed to examine the effect of B2 receptor antagonism on Bi
agonist mediated responses.
7.6.3 KininMetabolism
Inhibition of ACE augments the vasodilator and fibrinolytic effects of bradykinin in
patients with heart failure. We have clearly demonstrated that bradykinin contributes
to the systemic haemodynamic effects of ACE inhibition in this population.
Consistent with the hypothesis that inhibiting additional enzymes responsible for the
metabolism of plasma bradykinin may be beneficial in patients with heart failure, we
have demonstrated that combined inhibition of ACE and NEP potentiates the
vascular actions of bradykinin to a greater extent than ACE inhibition alone.
The absence of a significant treatment benefit with combined ACE and NEP
inhibition in the OVERTURE trial [Packer et al, 2002] may reflect the broad
substrate specificity of NEP [Roques et al, 1993], Inhibition of NEP will result not
only in accumulation of plasma bradykinin but alters plasma concentrations of a
number of vasoactive peptides including atrial natriuretic peptide, substance P,
angiotensin II and endothelin-1 [Roques et al, 1993; Ferro et al, 1998], Targeting a
143
bradykinin metabolising enzyme with more restricted substrate specificity may
afford greater therapeutic benefit in patients with heart failure. Three such candidate
enzymes are aminopeptidase P, carboxypeptidase N and carboxypeptidase B.
7.6.3.1 Aminopeptidase P
Aminopeptidase P is a zinc metallopeptidase that inactivates bradykinin by cleaving
the N terminal Arg^Pro2 bond (Figure 24) [Hooper et al, 1992; Simmons and
Orawski, 1992], Aminopeptidase P exists both in a membrane-bound form and a
cytosolic form [Yoshimoto et al, 1994], is present on the plasma membrane of human
vascular endothelial cells [Ryan et al, 1996] and is thought to contribute to the
degradation of bradykinin in the pulmonary and coronary circulations [Ryan et al,
1994],
Inhibition of aminopeptidase P blocks bradykinin degradation in a number of
vascular beds in vitro. In rodents in vivo, inhibition of aminopeptidase P in the
pulmonary circulation increases plasma bradykinin concentrations [Ryan et al, 1994],
whilst systemic aminopeptidase P inhibition augments the vasodepressor response to
intravenous, but not intra-arterial, bradykinin [Kitamura et al, 1999]. Furthermore,
apastatin, a selective inhibitor of aminopeptidase P, reduces myocardial infarct size
by a kinin-dependent pathway in rodent models of myocardial ischaemia and
reperfusion, both alone and in combination with ACE inhibition [Wolfrum et al,
2001; Veeravalli et al, 2003].
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Figure 24. Chemical structure of bradykinin and additional sites of enzymatic cleavage. TAFI, Thrombin
activatable fibrinolysis inhibitor.
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In man, lower plasma aminopeptidase P activity is associated with a previous history
of angio-oedema [Adam et al, 2002] and co-administration of apstatin and ACE
inhibition markedly augments the bradykinin wheal response compared to either
inhibitor alone [Kim et al, 2000], Further work is required to determine whether
inhibition of aminopeptidase P, in combination with ACE inhibition, augments the
vascular actions of bradykinin in the human peripheral and systemic circulations in
vivo to a greater extent than ACE inhibition alone.
7.6.3.2 Carboxypeptidase N
Synthesised in the liver and secreted into the circulation in its active form,
carboxypeptidase N is a constitutively active metallocarboxypeptidase that cleaves
several biologically active peptides and proteins including bradykinin,
anaphylatoxins (C3a, C4a and C5a) and fibrinopeptides A and B, by removing the C-
terminal arginine or lysine residues (Figure 24). In human plasma, carboxypeptidase
N contributes to <10% of bradykinin metabolism at low concentrations of the
nonapeptide [Kuoppala et al, 2000], However, at higher concentrations of
bradykinin, the contribution of carboxypeptidase N to bradykinin degradation is
significantly increased [Kuoppala et al, 2000], As with aminopeptidase P, it remains
to be determined whether inhibition of carboxypeptidase N augments the vascular
actions of bradykinin.
7.6.3.3 Carboxypeptidase B (Thrombin Activatable Fibrinolysis Inhibitor)
Plasma carboxypeptidase B, or thrombin activatable fibrinolysis inhibitor, is another
metallocarboxypeptidase present in plasma. Carboxypeptidase B is synthesised in the
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liver, but unlike the constitutively active carboxypeptidase N, is secreted into the
circulation as an inactive pro-enzyme precursor [Bouma et al, 2001], In the presence
of thrombus formation and in particular, the thrombin-thrombomodulin complex,
carboxypeptidase B undergo proteolytic conversion to its active form [Bouma et al,
2001]. Once activated carboxypeptidase B preferentially hydrolyses basic amino
acids, removing the C-terminal arginine or lysine residue from a number of
substrates including bradykinin (Figure 24), the enkephalins and partially degraded
fibrin. In addition to reducing bradykinin-mediated endothelial t-PA release,
carboxypeptidase B directly inhibits t-PA mediated fibrinolysis at sites of thrombus
formation by removing the C-terminal lysine residues from partially degraded fibrin,
thus preventing the binding of t-PA [Bouma et al, 2001], Interestingly,
carboxypeptidase B hydrolyses bradykinin in vitro as efficiently as it does plasmin
cleaved fibrin peptides, and more effectively than carboxypeptidase N [Myles et al,
2003].
Besides the potentially beneficial effects attributable to the inhibition of bradykinin
metabolism, inhibitors of carboxypeptidase B may confer additional therapeutic
benefits in patients receiving thrombolytic therapy for acute myocardial infarction. In
almost a third of these patients, fibrinolytic therapy fails to restore satisfactory
reperfusion of the occluded vessel [DeWood et al, 1980]. The presence of a
persistently occluded coronary artery is associated with increased rates of mortality
and left ventricular dysfunction [GUSTO, 1993 ], Plasma concentrations of activated
carboxypeptidase B are elevated during thrombosis and thrombolysis administration
[Redlitz et al, 1996] and in animal models, inhibition of carboxypeptidase B with the
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selective antagonist, potato carboxypeptidase inhibitor, enhances t-PA mediated clot
lysis [Klement et al, 1999; Nagashima et al, 2000; Refino et al, 2000], We have
recently demonstrated that inhibition of carboxypeptidase B augments t-PA mediated
fibrinolysis in human whole blood in vitro [Cruden et al, 2005], Thus inhibition of
carboxypeptidase B may be a novel therapeutic adjunct to thrombolytic therapy in
man.
Inhibitors of carboxypeptidase B may also have a role in the secondary prevention of
atherosclerotic vascular disease. Low circulating fibrinolytic activity is associated
with an increased risk ofmyocardial infarction in young men [Meade et al, 1993] and
predicts which patients with unstable angina will progress to myocardial infarction
[Munkvad et al, 1990]. Acute endothelial t-PA release is impaired in smokers
[Newby et al, 1999; Pretorius et al, 2002] and patients with coronary artery disease
[Newby et al, 2001], and the degree of impairment correlates with atheromatous
plaque load [Newby et al, 2001], In patients with atheromatous vascular disease,
inhibition of carboxypeptidase B may augment endogenous fibrinolytic activity,
shifting the balance in favour of clot dissolution rather than propagation, and
interrupting the cycle of sub-clinical thrombus formation, organisation and vessel
remodelling that underlies chronic atheromatous plaque growth [Mann and Davies,
1999],
To date, however, there has been no assessment of the contribution of
carboxypeptidase B to bradykinin metabolism and inhibition of t-PA mediated
fibrinolysis in vivo in man.
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The Badimon chamber provides a powerful and elegant method of assessing ex vivo
thrombus formation in an extracorporeal flow chamber [Badimon et al, 1999]. The
technique utilises a continuous flow of venous effluent blood that is passed into a
series of chambers containing a thrombogenic surface usually consisting of denuded
porcine aortic strips. The characteristics of the flow chamber can be modified to
generate low and high shear stress conditions that generate fibrin or platelet rich
thrombi respectively. Using this model, the effects of inhibition of a number of
biological pathways including the glycoprotein Ilb/IIIa receptor [Lev et al, 2004],
HMG-CoA reductase and cholesterol synthesis [Dangas et al, 1999], thrombin
[Sarich et al, 2003] and tissue factor [Badimon et al, 1999] on thrombus formation ex
vivo have been examined.
We propose to expose venous effluent from the bradykinin-infused human forearm
model to the Badimon Chamber. The resultant model will permit a direct assessment
of the effects of bradykinin-mediated endothelial t-PA release on acute dynamic
formation of thrombus formation in man. Using this model, we intend to examine the
effect of selective carboxypeptidase B inhibition on thrombus formation in the
presence of endogenous bradykinin-induced t-PA. This work is being undertaken as
part of a British Heart Foundation research programme (BHF PG/04/131).
7.6.4 Cardiac Effects of Bradykinin and ACE Inhibition
In contrast to endothelial-mediated vasomotor and fibrinolytic function, the effects of
bradykinin and ACE inhibition on myocardial contractility in man remain unclear.
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Bradykinin exerts a negative inotropic effect on porcine atrial myoctyes in vitro
[Tom et al, 2001] and ex vivo [Baydoun and Woodward, 1991], and its antagonism
in vivo attenuates left ventricular relaxation and contractile performance both in the
presence [Fujii et al, 2002] and absence of ACE inhibition in models of heart failure
[Cheng et al, 1998]. In a canine model of pacing induced congestive heart failure,
chronic bradykinin infusion preserves left ventricular systolic and diastolic function
and delays the progression of heart failure [Tonduangu et al, 2004].
In ex vivo animal models, ACE inhibition reduces basal left ventricular contractility
and improves left ventricular relaxation via a B2 receptor and nitric oxide dependent
mechanism [Anning et al, 1995; Cargnoni et al, 2001], Although the effects on basal
myocardial contractility in man are not known, acute ACE inhibition attenuates the
beta-adrenergic mediated increase in contractility by a nitric oxide dependent
pathway in patients with dilated cardiomyopathy, but not control subjects [Wittstein
et al, 2001]. It remains to be established whether bradykinin contributes to the
cardiac effects of ACE inhibition in vivo in man. Using a validated micromanometer
tipped left ventricular impedance catheter to enable real time pressure volume
measurement within the left ventricular cavity in vivo, we intend to examine the
1
effect of acute intra-coronary bradykinin antagonism on myocardial contractility in
the normal and failing human heart in the presence or absence of ACE inhibition in
patients undergoing elective diagnostic coronary angiography.
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7.7 CLINICAL RELEVANCE
The major benefits associated with ACE inhibitor therapy in patients with heart
failure and vascular disease are well established [CONSENSUS, 1987; Flather et al,
2000; Yusuf et al, 2000; Fox, 2003]. We have convincingly demonstrated that
bradykinin contributes to the systemic haemodynamic effects of ACE inhibition.
Moreover, we have shown that systemic ACE inhibition significantly augments
bradykinin-mediated vasodilatation and endothelial t-PA release in these patients and
these effects appear to be restricted to the vascular B2 kinin receptor. These data
provide further support for the hypothesis that bradykinin is an important mediator of
the anti-ischaemic effects ofACE inhibition in patients with cardiovascular disease.
Besides ACE, bradykinin is metabolised by a number of enzyme systems in plasma.
We have shown that inhibition of one such enzyme, NEP, in combination with ACE
inhibition augments bradykinin-mediated vasodilatation and endothelial t-PA release
in the peripheral circulation of patients with heart failure to a greater extent than
ACE inhibition alone. Neutral endopeptidase, however, is involved in the
metabolism of a large number of vasoactive peptides and this lack of substrate
specificity would appear to limit the potential therapeutic benefits of additional
bradykinin accumulation in large scale trials of combined ACE and NEP inhibition
in patients with heart failure [Packer et al, 2002], Pharmacological strategies
targeting bradykinin metabolism and the B2 kinin receptor more specifically may
afford greater cardiovascular protection.
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On a more cautious note, it should be noted that potentiating the vascular actions of
bradykinin may have detrimental effects. Bradykinin has been implicated in the
pathogenesis of ACE inhibitor-mediated angio-oedema [Nussberger et al, 1998],
Moreover, compared to ACE inhibition an even greater incidence of angio-oedema
has been reported following treatment with combined ACE and NEP inhibition
[Armstrong et al, 2002], Further work is required to establish the role of bradykinin
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